WO2015141827A1 - 心筋細胞の選別方法 - Google Patents
心筋細胞の選別方法 Download PDFInfo
- Publication number
- WO2015141827A1 WO2015141827A1 PCT/JP2015/058466 JP2015058466W WO2015141827A1 WO 2015141827 A1 WO2015141827 A1 WO 2015141827A1 JP 2015058466 W JP2015058466 W JP 2015058466W WO 2015141827 A1 WO2015141827 A1 WO 2015141827A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mirna
- gene
- mrna
- cardiomyocytes
- cells
- Prior art date
Links
- 210000004413 cardiac myocyte Anatomy 0.000 title claims abstract description 194
- 238000000034 method Methods 0.000 title claims abstract description 155
- 210000004027 cell Anatomy 0.000 claims abstract description 299
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 269
- 108091070501 miRNA Proteins 0.000 claims abstract description 242
- 239000002679 microRNA Substances 0.000 claims abstract description 239
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 228
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 68
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 59
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 59
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 43
- 108091026890 Coding region Proteins 0.000 claims abstract description 35
- 238000004519 manufacturing process Methods 0.000 claims abstract description 28
- 238000013519 translation Methods 0.000 claims abstract description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 5
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 claims description 46
- 230000001939 inductive effect Effects 0.000 claims description 37
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 31
- 206010059866 Drug resistance Diseases 0.000 claims description 28
- 238000000746 purification Methods 0.000 claims description 25
- 108091006047 fluorescent proteins Proteins 0.000 claims description 23
- 229950010131 puromycin Drugs 0.000 claims description 23
- 230000006907 apoptotic process Effects 0.000 claims description 22
- 102000034287 fluorescent proteins Human genes 0.000 claims description 22
- 238000012258 culturing Methods 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 16
- 108091048941 miR-499a stem-loop Proteins 0.000 claims description 16
- 108091028606 miR-1 stem-loop Proteins 0.000 claims description 15
- 108091005948 blue fluorescent proteins Proteins 0.000 claims description 14
- 230000003115 biocidal effect Effects 0.000 claims description 11
- 239000003242 anti bacterial agent Substances 0.000 claims description 10
- 229930189065 blasticidin Natural products 0.000 claims description 7
- 108091071651 miR-208 stem-loop Proteins 0.000 claims description 7
- 108091084446 miR-208a stem-loop Proteins 0.000 claims description 7
- 108091062547 miR-208a-1 stem-loop Proteins 0.000 claims description 7
- 108091055375 miR-208a-2 stem-loop Proteins 0.000 claims description 7
- 108091047268 miR-208b stem-loop Proteins 0.000 claims description 7
- 108700026220 vif Genes Proteins 0.000 claims description 5
- 239000003550 marker Substances 0.000 description 52
- 239000002609 medium Substances 0.000 description 45
- 239000000243 solution Substances 0.000 description 28
- 230000014509 gene expression Effects 0.000 description 25
- 230000004069 differentiation Effects 0.000 description 23
- 229910052760 oxygen Inorganic materials 0.000 description 23
- 210000000130 stem cell Anatomy 0.000 description 23
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 22
- 239000001301 oxygen Substances 0.000 description 22
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 21
- 210000001082 somatic cell Anatomy 0.000 description 21
- 102000004987 Troponin T Human genes 0.000 description 20
- 108090001108 Troponin T Proteins 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 19
- 238000012408 PCR amplification Methods 0.000 description 19
- 239000000126 substance Substances 0.000 description 19
- 230000002107 myocardial effect Effects 0.000 description 18
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 16
- 239000003112 inhibitor Substances 0.000 description 15
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 14
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 14
- 239000013598 vector Substances 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 13
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 13
- 230000008672 reprogramming Effects 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 108020003589 5' Untranslated Regions Proteins 0.000 description 12
- 229930182816 L-glutamine Natural products 0.000 description 12
- 102000004142 Trypsin Human genes 0.000 description 12
- 108090000631 Trypsin Proteins 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 12
- 239000012588 trypsin Substances 0.000 description 12
- 102000004338 Transferrin Human genes 0.000 description 11
- 108090000901 Transferrin Proteins 0.000 description 11
- 239000012581 transferrin Substances 0.000 description 11
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 10
- 208000019622 heart disease Diseases 0.000 description 10
- 230000006698 induction Effects 0.000 description 10
- 230000036961 partial effect Effects 0.000 description 10
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 10
- 108020005345 3' Untranslated Regions Proteins 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000007640 basal medium Substances 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 102000013814 Wnt Human genes 0.000 description 8
- 108050003627 Wnt Proteins 0.000 description 8
- 229960005070 ascorbic acid Drugs 0.000 description 8
- 235000010323 ascorbic acid Nutrition 0.000 description 8
- 239000011668 ascorbic acid Substances 0.000 description 8
- 238000004020 luminiscence type Methods 0.000 description 8
- 108060005980 Collagenase Proteins 0.000 description 7
- 102000029816 Collagenase Human genes 0.000 description 7
- -1 Fbx15 Proteins 0.000 description 7
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 7
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 229960002424 collagenase Drugs 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 238000002493 microarray Methods 0.000 description 7
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 7
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 6
- 108700026244 Open Reading Frames Proteins 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 239000003797 essential amino acid Substances 0.000 description 6
- 235000020776 essential amino acid Nutrition 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 239000005090 green fluorescent protein Substances 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 5
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 5
- 108091027967 Small hairpin RNA Proteins 0.000 description 5
- 108020004459 Small interfering RNA Proteins 0.000 description 5
- 108091081024 Start codon Proteins 0.000 description 5
- 108010023082 activin A Proteins 0.000 description 5
- 210000002459 blastocyst Anatomy 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 210000002242 embryoid body Anatomy 0.000 description 5
- 210000004602 germ cell Anatomy 0.000 description 5
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 5
- 210000001161 mammalian embryo Anatomy 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000010187 selection method Methods 0.000 description 5
- 239000004055 small Interfering RNA Substances 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- XVMHQSDMKWQNBK-UHFFFAOYSA-N 2-[[3-(4-fluorophenyl)-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl]sulfanyl]-n-(6-methyl-1,3-benzothiazol-2-yl)acetamide Chemical compound S1C2=CC(C)=CC=C2N=C1NC(=O)CSC1=NC=2CCSC=2C(=O)N1C1=CC=C(F)C=C1 XVMHQSDMKWQNBK-UHFFFAOYSA-N 0.000 description 4
- 208000031229 Cardiomyopathies Diseases 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 4
- 208000009525 Myocarditis Diseases 0.000 description 4
- 241000288906 Primates Species 0.000 description 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
- 210000004102 animal cell Anatomy 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 239000012737 fresh medium Substances 0.000 description 4
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 4
- 238000001638 lipofection Methods 0.000 description 4
- 230000004807 localization Effects 0.000 description 4
- 238000000520 microinjection Methods 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000012096 transfection reagent Substances 0.000 description 4
- RHUJMHOIQBDFQR-UHFFFAOYSA-N 2-[[3-(2-methoxyphenyl)-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl]sulfanyl]-n-(6-methyl-1,3-benzothiazol-2-yl)acetamide Chemical compound COC1=CC=CC=C1N1C(=O)C(SCC2)=C2N=C1SCC(=O)NC1=NC2=CC=C(C)C=C2S1 RHUJMHOIQBDFQR-UHFFFAOYSA-N 0.000 description 3
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 239000012583 B-27 Supplement Substances 0.000 description 3
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 3
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 3
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 102000003964 Histone deacetylase Human genes 0.000 description 3
- 108090000353 Histone deacetylase Proteins 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 102000006830 Luminescent Proteins Human genes 0.000 description 3
- 108010047357 Luminescent Proteins Proteins 0.000 description 3
- 239000012580 N-2 Supplement Substances 0.000 description 3
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 238000010208 microarray analysis Methods 0.000 description 3
- 229960004857 mitomycin Drugs 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000004114 suspension culture Methods 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 2
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 2
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 2
- 102100038511 AT-rich interactive domain-containing protein 3A Human genes 0.000 description 2
- 108060000903 Beta-catenin Proteins 0.000 description 2
- 102000015735 Beta-catenin Human genes 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000013392 Carboxylesterase Human genes 0.000 description 2
- 108010051152 Carboxylesterase Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 2
- 102000000311 Cytosine Deaminase Human genes 0.000 description 2
- 108010080611 Cytosine Deaminase Proteins 0.000 description 2
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 2
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 2
- 102000053187 Glucuronidase Human genes 0.000 description 2
- 108010060309 Glucuronidase Proteins 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 102100039996 Histone deacetylase 1 Human genes 0.000 description 2
- 101000808887 Homo sapiens AT-rich interactive domain-containing protein 3A Proteins 0.000 description 2
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- 102000007547 Laminin Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 2
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 2
- 102000004459 Nitroreductase Human genes 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 229930185560 Pseudouridine Natural products 0.000 description 2
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 2
- 102000030764 Purine-nucleoside phosphorylase Human genes 0.000 description 2
- 101710132082 Pyrimidine/purine nucleoside phosphorylase Proteins 0.000 description 2
- 101150086694 SLC22A3 gene Proteins 0.000 description 2
- 102100021117 Serine protease HTRA2, mitochondrial Human genes 0.000 description 2
- 102100031372 Thymidine phosphorylase Human genes 0.000 description 2
- 101900150902 Varicella-zoster virus Thymidine kinase Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 210000004507 artificial chromosome Anatomy 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 108010082025 cyan fluorescent protein Proteins 0.000 description 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 108010062699 gamma-Glutamyl Hydrolase Proteins 0.000 description 2
- 210000000688 human artificial chromosome Anatomy 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108091073532 miR-143 stem-loop Proteins 0.000 description 2
- 108091087492 miR-490 stem-loop Proteins 0.000 description 2
- 108091036400 miR-490-1 stem-loop Proteins 0.000 description 2
- 108091057695 miR-490-2 stem-loop Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 108020001162 nitroreductase Proteins 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 2
- 229960000604 valproic acid Drugs 0.000 description 2
- JUNHQBJCWZVSAT-BQYQJAHWSA-N (e)-n-hydroxy-3-[1-methyl-4-(4-methylbenzoyl)pyrrol-2-yl]prop-2-enamide Chemical compound C1=CC(C)=CC=C1C(=O)C1=CN(C)C(\C=C\C(=O)NO)=C1 JUNHQBJCWZVSAT-BQYQJAHWSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100040124 Apoptosis-inducing factor 1, mitochondrial Human genes 0.000 description 1
- QPYLCLZBJGCFNT-VPCXQMTMSA-N C1=CC(N)=NC(=O)N1[C@]1(C)O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O Chemical compound C1=CC(N)=NC(=O)N1[C@]1(C)O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O QPYLCLZBJGCFNT-VPCXQMTMSA-N 0.000 description 1
- 108091016585 CD44 antigen Proteins 0.000 description 1
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 1
- 101100257372 Caenorhabditis elegans sox-3 gene Proteins 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102000016362 Catenins Human genes 0.000 description 1
- 108010067316 Catenins Proteins 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- PCDQPRRSZKQHHS-CCXZUQQUSA-N Cytarabine Triphosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-CCXZUQQUSA-N 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000003849 Cytochrome P450 Human genes 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101710101225 Diablo IAP-binding mitochondrial protein Proteins 0.000 description 1
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 108091005941 EBFP Proteins 0.000 description 1
- 102100021008 Endonuclease G, mitochondrial Human genes 0.000 description 1
- 101150099612 Esrrb gene Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 102000027587 GPCRs class F Human genes 0.000 description 1
- 108091008884 GPCRs class F Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 108010052199 HLA-C Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 101001023784 Heteractis crispa GFP-like non-fluorescent chromoprotein Proteins 0.000 description 1
- 102000011787 Histone Methyltransferases Human genes 0.000 description 1
- 108010036115 Histone Methyltransferases Proteins 0.000 description 1
- 101000871228 Homo sapiens Diablo IAP-binding mitochondrial protein Proteins 0.000 description 1
- 101000864646 Homo sapiens Dickkopf-related protein 1 Proteins 0.000 description 1
- 101000977692 Homo sapiens Iroquois-class homeodomain protein IRX-6 Proteins 0.000 description 1
- 101000958741 Homo sapiens Myosin-6 Proteins 0.000 description 1
- 101000595669 Homo sapiens Pituitary homeobox 2 Proteins 0.000 description 1
- 101000777245 Homo sapiens Undifferentiated embryonic cell transcription factor 1 Proteins 0.000 description 1
- ZGSXEXBYLJIOGF-ALFLXDJESA-N IWR-1-endo Chemical compound C=1C=CC2=CC=CN=C2C=1NC(=O)C(C=C1)=CC=C1N1C(=O)[C@@H]2[C@H](C=C3)C[C@H]3[C@@H]2C1=O ZGSXEXBYLJIOGF-ALFLXDJESA-N 0.000 description 1
- 102100023527 Iroquois-class homeodomain protein IRX-6 Human genes 0.000 description 1
- 101150072501 Klf2 gene Proteins 0.000 description 1
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 101710151321 Melanostatin Proteins 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 101100144701 Mus musculus Drosha gene Proteins 0.000 description 1
- 101100310657 Mus musculus Sox1 gene Proteins 0.000 description 1
- 101100310648 Mus musculus Sox17 gene Proteins 0.000 description 1
- 101100257376 Mus musculus Sox3 gene Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038319 Myosin-6 Human genes 0.000 description 1
- AOKQNZVJJXPUQA-KQYNXXCUSA-N N(7)-methylguanosine 5'-phosphate Chemical compound C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@H](COP(O)([O-])=O)[C@@H](O)[C@H]1O AOKQNZVJJXPUQA-KQYNXXCUSA-N 0.000 description 1
- WRKPZSMRWPJJDH-UHFFFAOYSA-N N-(6-methyl-1,3-benzothiazol-2-yl)-2-[(4-oxo-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)thio]acetamide Chemical compound S1C2=CC(C)=CC=C2N=C1NC(=O)CSC1=NC=2CCSC=2C(=O)N1C1=CC=CC=C1 WRKPZSMRWPJJDH-UHFFFAOYSA-N 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- 101150072008 NR5A2 gene Proteins 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- 102100037369 Nidogen-1 Human genes 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102100036090 Pituitary homeobox 2 Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- 102100034201 Sclerostin Human genes 0.000 description 1
- 108050006698 Sclerostin Proteins 0.000 description 1
- 101710146118 Serine protease HTRA2, mitochondrial Proteins 0.000 description 1
- 101150001847 Sox15 gene Proteins 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 101150111019 Tbx3 gene Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 1
- 102000004903 Troponin Human genes 0.000 description 1
- 108090001027 Troponin Proteins 0.000 description 1
- PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 description 1
- 102100031278 Undifferentiated embryonic cell transcription factor 1 Human genes 0.000 description 1
- 230000004156 Wnt signaling pathway Effects 0.000 description 1
- KLGQSVMIPOVQAX-UHFFFAOYSA-N XAV939 Chemical compound N=1C=2CCSCC=2C(O)=NC=1C1=CC=C(C(F)(F)F)C=C1 KLGQSVMIPOVQAX-UHFFFAOYSA-N 0.000 description 1
- VEWJOCYCKIZKKV-GBNDHIKLSA-N [[(2r,3s,4r,5s)-5-(2,4-dioxo-1h-pyrimidin-5-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1C1=CNC(=O)NC1=O VEWJOCYCKIZKKV-GBNDHIKLSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 108010076089 accutase Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
- 239000005667 attractant Substances 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 102000055574 bcl-2 Homologous Antagonist-Killer Human genes 0.000 description 1
- 102000055102 bcl-2-Associated X Human genes 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000000801 calcium channel stimulating agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000005258 dental pulp stem cell Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 239000003968 dna methyltransferase inhibitor Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 108010047964 endonuclease G Proteins 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000000597 exocrine pancreas cell Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 108010021843 fluorescent protein 583 Proteins 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 210000002980 germ line cell Anatomy 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 239000003572 glycogen synthase kinase 3 inhibitor Substances 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 108010028309 kalinin Proteins 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 101150111214 lin-28 gene Proteins 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 239000003697 methyltransferase inhibitor Substances 0.000 description 1
- 108091072810 miR-294 stem-loop Proteins 0.000 description 1
- 108091076076 miR-295 stem-loop Proteins 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000025608 mitochondrion localization Effects 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 229940028444 muse Drugs 0.000 description 1
- FMURUEPQXKJIPS-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-6,7-dimethoxy-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-4-amine;trihydrochloride Chemical compound Cl.Cl.Cl.C=12C=C(OC)C(OC)=CC2=NC(N2CCN(C)CCC2)=NC=1NC(CC1)CCN1CC1=CC=CC=C1 FMURUEPQXKJIPS-UHFFFAOYSA-N 0.000 description 1
- JJEDWBQZCRESJL-DEDYPNTBSA-N n-[(e)-(5-methylfuran-2-yl)methylideneamino]-2-phenoxybenzamide Chemical compound O1C(C)=CC=C1\C=N\NC(=O)C1=CC=CC=C1OC1=CC=CC=C1 JJEDWBQZCRESJL-DEDYPNTBSA-N 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 108010008217 nidogen Proteins 0.000 description 1
- 231100001143 noxa Toxicity 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 108091007428 primary miRNA Proteins 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- UQOQENZZLBSFKO-POPPZSFYSA-N prostaglandin J2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)C=CC1=O UQOQENZZLBSFKO-POPPZSFYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 210000001988 somatic stem cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229950010342 uridine triphosphate Drugs 0.000 description 1
- PGAVKCOVUIYSFO-UHFFFAOYSA-N uridine-triphosphate Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Definitions
- the present invention relates to a novel cardiomyocyte sorting method.
- the present invention also relates to a method for producing high-purity cardiomyocytes and a kit therefor.
- ES cells embryonic stem cells
- iPS cells induced pluripotent stem cells
- Non-Patent Document 2 Non-Patent Document 3, Patent Document 3. 4 and Patent Document 5).
- an object of the present invention is to provide a novel method for selecting cardiomyocytes.
- Another object of the present invention is to provide a method for producing high-purity cardiomyocytes and a kit therefor.
- cardiomyocytes can be purified with high purity.
- cells differentiated from pluripotent stem cells were sorted into cardiomyocytes and non-cardiomyocytes and subjected to miRNA microarray analysis.
- miRNA-responsive off-switch mRNAs corresponding to these miRNAs were prepared, and the mRNAs were introduced into the cells to be selected, and then the myocardial cells were selected to purify the cardiomyocytes with extremely high purity. Succeeded in doing.
- cardiomyocytes can be purified with high purity without going through a FACS sorting step.
- the present invention has been completed based on such findings.
- a method for sorting cardiomyocytes including a step of introducing miRNA-responsive mRNA into a cell group , wherein the miRNA-responsive mRNA is: (i) a nucleic acid specifically recognized by miRNA specifically expressed in cardiomyocytes, and (ii) consisting of a sequence comprising a nucleic acid corresponding to the coding region of the gene, Wherein the translation of the nucleic acid corresponding to the coding region of the gene of (ii) into a protein is controlled by the nucleic acid sequence of (i).
- the miRNA-responsive mRNA is an miRNA-responsive off-switch mRNA.
- the miRNA specifically expressed in the cardiomyocytes of (i) is one or more selected from the group consisting of miR-1, miR-208a, miR-208b and miR-499a-5p
- the gene (ii) is one or more genes selected from the group consisting of a gene encoding a fluorescent protein, an apoptosis-inducing gene, and a suicide gene The method described in 1.
- the gene encoding the fluorescent protein is a gene encoding blue fluorescent protein (BFP).
- BFP blue fluorescent protein
- apoptosis-inducing gene is a gene encoding a Bim protein.
- the drug resistance gene is an antibiotic resistance gene.
- the antibiotic resistance gene is a puromycin resistance gene or a blasticidin resistance gene.
- a method for producing cardiomyocytes comprising: (a) introducing miRNA-responsive mRNA into a cell population, and (b) including a step of selecting the cell based on the amount of the protein translated from the mRNA of step (a),
- the miRNA-responsive mRNA is: (i) a nucleic acid specifically recognized by miRNA specifically expressed in cardiomyocytes, and (ii) consisting of a sequence comprising a nucleic acid corresponding to the coding region of the gene, A method wherein high-purity cardiomyocytes are obtained as compared to the case where the steps (a) and (b) are not performed.
- the method according to (12), wherein the miRNA-responsive mRNA is an miRNA-responsive off-switch mRNA.
- the miRNA specifically expressed in the cardiomyocytes of (i) is one or more selected from the group consisting of miR-1, miR-208a, miR-208b and miR-499a-5p
- the gene of (ii) is a gene encoding a fluorescent protein.
- a method for producing cardiomyocytes comprising: (a) introducing an mRNA comprising a sequence containing a miRNA-responsive mRNA and a nucleic acid corresponding to a coding region of a drug resistance gene into a cell group; and (b) culturing the cells obtained in step (a) in the presence of a drug corresponding to the drug resistance gene of step (a),
- the miRNA-responsive mRNA is: (i) a nucleic acid specifically recognized by miRNA specifically expressed in cardiomyocytes, and (ii) consisting of a sequence comprising a nucleic acid corresponding to the coding region of the gene, A method wherein high-purity cardiomyocytes are obtained as compared to the case where the steps (a) and (b) are not performed.
- the method according to (19), wherein the miRNA-responsive mRNA is an miRNA-responsive off-switch mRNA.
- the miRNA specifically expressed in the cardiomyocytes of (i) is one or more selected from the group consisting of miR-1, miR-208a, miR-208b and miR-499a-5p
- the cardiomyocytes can be easily selected and purified to high purity by the method shown in the present invention. Since the mRNA introduced into the cell group by the method of the present invention is present in the cell only transiently, it is possible to safely select cardiomyocytes without being integrated into the genome. Moreover, it is possible to select a living cell based on the expression level of miRNA in an activated state in the cell without immobilizing the cell by the method shown in the present invention.
- cardiomyocytes obtained by the method for producing cardiomyocytes of the present invention heart failure, ischemic heart disease, myocardial infarction, cardiomyopathy, myocarditis, hypertrophic cardiomyopathy, dilated phase fertilizer It becomes possible to treat heart diseases such as large cardiomyopathy and dilated cardiomyopathy.
- FIG. 1 shows miRNA microarray results of GFP positive cells (cardiomyocytes) and GFP negative cells (non-cardiomyocytes).
- A The left figure shows the result of miRNA microarray of cells collected by FACS on the 20th day from the start of differentiation induction, and the right figure shows the result of miRNA microarray of cells collected by FACS on the 8th day from the start of differentiation induction. It is.
- B On the 8th and 20th day from the start of differentiation induction, the Venn diagram of miRNA that was significantly expressed in GFP positive cells is shown.
- FIG. 2 shows the results of analysis using miRNA-responsive off-switch mRNA.
- FIG. 3 shows the results of examining the effectiveness of miRNA-responsive off-switch mRNA in the purification of cardiomyocytes. Using TNT specifically expressed in cardiomyocytes as an index, the degree of purification of cardiomyocytes was examined.
- FIG. 4 shows the results of examining the effectiveness of miRNA-responsive off-switch mRNA in the purification of cardiomyocytes in cell populations that have undergone the process of inducing differentiation from various types of pluripotent stem cells (PSCs) into cardiomyocytes. Using TNT specifically expressed in cardiomyocytes as an index, the degree of purification of cardiomyocytes was examined. mRNA containing no miRNA-responsive sequence was used as a control.
- FIG. 5 shows the results of examining the expression state of a myocardial specific gene in cells selected using miR-1 responsive off-switch mRNA. Expression analysis was performed by quantitative RT-PCR.
- FIG. 6 shows the results of examining the expression level of a myocardial specific gene at the protein level in cells selected using miR-1-, miR-208a- and miR-499a-5p-responsive off-switch mRNAs. . Analysis was performed by immunostaining for TNT.
- FIG. 7 shows the results of examining the expression state of the miR-1 target gene when miR-1-responsive off-switch mRNA is introduced and when it is not introduced. After analysis by microarray, 54 miR-1 target genes were evaluated.
- FIG. 8 shows the results of examining the effectiveness of cardiomyocyte purification in the case of combining a plurality of miRNA-responsive off-switch mRNAs.
- TNT specifically expressed in cardiomyocytes as an index
- the degree of purification of cardiomyocytes was examined.
- FIG. 9 shows the results of examining the cardiomyocyte purification effect when co-introducing miRNA-responsive off-switch mRNA and drug-resistant mRNA into cells.
- A Results when KhES1 is induced to differentiate.
- B Results when 409B2 is induced to differentiate.
- TNT specifically expressed in cardiomyocytes was examined.
- FIG. 2 shows the analysis results after co-introducing miR-1-, miR-208a-, miR-208b- and miR-499a-5p-responsive off-switch mRNA into cells derived from mouse heart with EGFP.
- a region surrounded by a line indicates a cardiomyocyte.
- the present invention provides a method for selecting cardiomyocytes, comprising the step of introducing miRNA-responsive mRNA into a cell group.
- the miRNA-responsive mRNA is introduced, and the cell group to be selected may be any cell that can contain cardiomyocytes.
- the cell group to be selected may be any cell that can contain cardiomyocytes.
- it may be a group of cells induced to differentiate from pluripotent stem cells or a group of cells taken out from the living body, but is not limited thereto. Therefore, miRNA-responsive mRNA may be introduced into a cell group in which it is unknown whether or not it contains cardiomyocytes.
- the cell group may be a cell group derived from pluripotent stem cells.
- a cell group induced to differentiate from a pluripotent stem cell is a cell group that has undergone a process of inducing differentiation from a pluripotent stem cell to a cardiomyocyte by the method described in detail later. And cells that have not been differentiated into cardiomyocytes.
- a pluripotent stem cell is not specifically limited, For example, the following are mentioned.
- Embryonic stem cells Embryonic stem cells (ES cells) are established from the inner cell mass of early embryos (eg, blastocysts) of mammals such as humans and mice, and have the ability to proliferate through self-replication. It has stem cells.
- ES cells are embryonic stem cells derived from the inner cell mass of the blastocyst, the embryo after the morula, in the 8-cell stage of a fertilized egg, and have the ability to differentiate into any cell that constitutes an adult, so-called differentiation. And ability to proliferate by self-replication.
- ES cells were discovered in mice in 1981 (MJ Evans and MH Kaufman (1981), Nature 292: 154-156), and then ES cell lines were established in primates such as humans and monkeys (JA Thomson et al. al. (1998), Science 282: 1145-1147; JA Thomson et al. (1995), Proc. Natl. Acad. Sci. USA, 92: 7844-7848; JA Thomson et al. (1996), Biol. Reprod., 55: 254-259; JA Thomson and VS Marshall (1998), Curr. Top. Dev. Biol., 38: 133-165).
- ES cells can be established by taking an inner cell mass from a blastocyst of a fertilized egg of a target animal and culturing the inner cell mass on a fibroblast feeder. In addition, maintenance of cells by subculture is performed using a culture solution to which substances such as leukemia inhibitory factor (LIF) and basic fibroblast growth factor (basic fibroblast growth factor (bFGF)) are added. It can be carried out.
- LIF leukemia inhibitory factor
- bFGF basic fibroblast growth factor
- DMEM / F-12 culture medium supplemented with 0.1 mM 2-mercaptoethanol, 0.1 mM non-essential amino acid, 2 mM L-glutamic acid, 20% KSR and 4 ng / ml bFGF is used as the culture medium for ES cell production.
- Human ES cells can be maintained in a humid atmosphere at 37 ° C., 5% CO 2 (H. Suemori et al. (2006), Biochem. Biophys. Res. Commun., 345: 926-932).
- ES cells also need to be passaged every 3-4 days, where passage is eg 0.25% trypsin and 0.1 mg / ml collagenase IV in PBS containing 1 mM CaCl 2 and 20% KSR. Can be used.
- ES cells can be generally selected by Real-Time PCR using the expression of gene markers such as alkaline phosphatase, Oct-3 / 4, Nanog as an index.
- gene markers such as alkaline phosphatase, Oct-3 / 4, Nanog
- OCT-3 / 4, NANOG, and ECAD can be used as an index (E. Kroon et al. (2008), Nat. Biotechnol., 26: 443). -452).
- Human ES cell lines for example, WA01 (H1) and WA09 (H9) are obtained from the WiCell Research Institute, and KhES-1, KhES-2 and KhES-3 are obtained from the Institute of Regenerative Medicine (Kyoto, Japan), Kyoto University Is possible.
- sperm stem cells are testis-derived pluripotent stem cells that are the origin of spermatogenesis. Like ES cells, these cells can be induced to differentiate into various types of cells, and have characteristics such as the ability to create chimeric mice when transplanted into mouse blastocysts (M. Kanatsu-Shinohara et al. ( 2003) Biol. Reprod., 69: 612-616; K. Shinohara et al. (2004), Cell, 119: 1001-1012).
- GDNF glial cell line-derived neurotrophic factor
- Embryonic germ cells are cells that are established from embryonic primordial germ cells and have the same pluripotency as ES cells, such as LIF, bFGF, stem cell factor, etc. It can be established by culturing primordial germ cells in the presence of these substances (Y. Matsui et al. (1992), Cell, 70: 841-847; JL Resnick et al. (1992), Nature, 359: 550 -551).
- iPS Artificial pluripotent stem cell
- iPS artificial pluripotent stem
- the reprogramming factor is a gene specifically expressed in ES cells, its gene product or non-cording RNA, a gene that plays an important role in maintaining undifferentiation of ES cells, its gene product or non-coding RNA, or It may be constituted by a low molecular compound.
- genes included in the reprogramming factor include Oct3 / 4, Sox2, Sox1, Sox3, Sox15, Sox17, Klf4, Klf2, c-Myc, N-Myc, L-Myc, Nanog, Lin28, Fbx15, ERas, ECAT15 -2, Tcl1, beta-catenin, Lin28b, Sall1, Sall4, Esrrb, Nr5a2, Tbx3 or Glis1 etc. are exemplified, and these reprogramming factors may be used alone or in combination.
- the reprogramming factors include histone deacetylase (HDAC) inhibitors [eg, small molecule inhibitors such as valproic acid (VPA), trichostatin A, sodium butyrate, MC 1293, M344, siRNA and shRNA against HDAC (eg Nucleic acid expression inhibitors such as HDAC1 siRNA Smartpool (registered trademark) (Millipore), HuSH 29mer shRNA Constructs against HDAC1 (OriGene), etc.], MEK inhibitors (eg PD184352, PD98059, U0126, SL327 and PD0325901), Glycogen synthase kinase-3 inhibitors (eg, Bio and CHIR99021), DNA methyltransferase inhibitors (eg, 5-azacytidine), histone methyltransferase inhibitors (eg, small molecule inhibitors such as BIX-01294, Suv39hl, Suv39h2, SetDBl And nucleic acid expression inhibitors such
- the reprogramming factor may be introduced into a somatic cell by a technique such as lipofection, fusion with a cell membrane-permeable peptide (for example, HIV-derived TAT and polyarginine), or microinjection.
- a cell membrane-permeable peptide for example, HIV-derived TAT and polyarginine
- Virus vectors include retrovirus vectors, lentivirus vectors (cell, 126, pp.663-676, 2006; Cell, 131, pp.861-872, 2007; Science, 318, pp.1917-1920, 2007 ), Adenovirus vectors (Science, 322, 945-949, 2008), adeno-associated virus vectors, Sendai virus vectors (WO 2010/008054) and the like.
- artificial chromosome vectors examples include human artificial chromosomes (HAC), yeast artificial chromosomes (YAC), and bacterial artificial chromosomes (BAC, PAC).
- HAC human artificial chromosomes
- YAC yeast artificial chromosomes
- BAC bacterial artificial chromosomes
- a plasmid a plasmid for mammalian cells can be used (Science, 322: 949-953, 2008).
- the vector can contain regulatory sequences such as a promoter, enhancer, ribosome binding sequence, terminator, polyadenylation site, etc. so that a nuclear reprogramming substance can be expressed.
- Selective marker sequences such as kanamycin resistance gene, ampicillin resistance gene, puromycin resistance gene, thymidine kinase gene, diphtheria toxin gene, reporter gene sequences such as green fluorescent protein (GFP), ⁇ -glucuronidase (GUS), FLAG, etc.
- GFP green fluorescent protein
- GUS ⁇ -glucuronidase
- FLAG FLAG
- the above vector has a LoxP sequence before and after the introduction of the gene into a somatic cell in order to excise the gene or promoter encoding the reprogramming factor and the gene encoding the reprogramming factor that binds to it. May be.
- RNA it may be introduced into somatic cells by techniques such as lipofection and microinjection, and in order to suppress degradation, RNA incorporating 5-methylcytidine and pseudouridine® (TriLink® Biotechnologies) is used. Yes (Warren L, (2010) Cell Stem Cell. 7: 618-630).
- a culture solution for inducing iPS cells for example, DMEM, DMEM / F12 or DME culture solution containing 10-15% FBS (in addition to these culture solutions, LIF, penicillin / streptomycin, puromycin, L- Glutamine, non-essential amino acids, ⁇ -mercaptoethanol, etc. may be included as appropriate.
- a commercially available culture medium for example, a culture medium for mouse ES cell culture (TX-WES culture medium, Thrombo X), primate ES Cell culture medium (primate ES / iPS cell culture medium, Reprocell), serum-free medium (mTeSR, Stemcell Technology).
- a somatic cell is brought into contact with a reprogramming factor on a DMEM or DMEM / F12 medium containing 10% FBS at 37 ° C. in the presence of 5% CO 2 for about 4 to 7 days. Then, re-spread the cells on feeder cells (for example, mitomycin C-treated STO cells, SNL cells, etc.), and use bFGF-containing primate ES cell culture medium about 10 days after contact between the somatic cells and the reprogramming factor. Culturing and generating iPS-like colonies about 30 to about 45 days or more after the contact.
- feeder cells for example, mitomycin C-treated STO cells, SNL cells, etc.
- 10% FBS-containing DMEM medium including LIF, penicillin / streptomycin, etc.
- feeder cells eg, mitomycin C-treated STO cells, SNL cells, etc.
- 5% CO 2 at 37 ° C. can be suitably included with puromycin, L-glutamine, non-essential amino acids, ⁇ -mercaptoethanol, etc.
- ES-like colonies after about 25 to about 30 days or more .
- somatic cells to be reprogrammed themselves are used (Takahashi K, et al. (2009), PLoS One. 4: e8067 or WO2010 / 137746), or extracellular matrix (eg, Laminin- 5 (WO2009 / 123349) and Matrigel (BD)) are exemplified.
- iPS cells may be established under hypoxic conditions (oxygen concentration of 0.1% or more and 15% or less) (Yoshida Y, et al. (2009), Cell Stem Cell. 5: 237 -241 or WO2010 / 013845).
- the culture medium is exchanged with a fresh culture medium once a day from the second day onward.
- the number of somatic cells used for nuclear reprogramming is not limited, but ranges from about 5 ⁇ 10 3 to about 5 ⁇ 10 6 cells per 100 cm 2 of culture dish.
- IPS cells can be selected according to the shape of the formed colonies.
- a drug resistance gene that is expressed in conjunction with a gene that is expressed when somatic cells are initialized for example, Oct3 / 4, Nanog
- a culture solution containing the corresponding drug selection The established iPS cells can be selected by culturing with the culture medium.
- the marker gene is a fluorescent protein gene
- iPS cells are selected by observing with a fluorescence microscope, in the case of a luminescent enzyme gene, by adding a luminescent substrate, and in the case of a chromogenic enzyme gene, by adding a chromogenic substrate can do.
- the term “somatic cell” refers to any animal cell (preferably, a mammalian cell including a human) except a germ line cell such as an egg, oocyte, ES cell, or totipotent cell.
- Somatic cells include, but are not limited to, fetal (pup) somatic cells, neonatal (pup) somatic cells, and mature healthy or diseased somatic cells. , Passage cells, and established cell lines.
- somatic cells include, for example, (1) neural stem cells, hematopoietic stem cells, mesenchymal stem cells, tissue stem cells such as dental pulp stem cells (somatic stem cells), (2) tissue progenitor cells, (3) lymphocytes, epithelium Cells, endothelial cells, muscle cells, fibroblasts (skin cells, etc.), hair cells, hepatocytes, gastric mucosal cells, enterocytes, spleen cells, pancreatic cells (exocrine pancreas cells, etc.), brain cells, lung cells, kidney cells Examples thereof include differentiated cells such as fat cells.
- somatic cells having the same or substantially the same HLA genotype as the transplant destination individual from the viewpoint that rejection does not occur.
- substantially the same means that the HLA genotype matches the transplanted cells to such an extent that an immune response can be suppressed by an immunosuppressive agent.
- HLA-A, HLA-B And somatic cells having an HLA type in which 3 loci of HLA-DR or 4 loci plus HLA-C are matched.
- ES cell derived from a cloned embryo obtained by nuclear transfer An ES cell derived from a cloned embryo obtained by nuclear transfer (nt ES cell) is an ES cell derived from a cloned embryo produced by nuclear transfer technology, It has almost the same properties as ES cells derived from fertilized eggs (T. Wakayama et al. (2001), Science, 292: 740-743; S. Wakayama et al. (2005), Biol. Reprod., 72 : 932-936; J. Byrne et al. (2007), Nature, 450: 497-502).
- an ES cell established from an inner cell mass of a clonal embryo-derived blastocyst obtained by replacing the nucleus of an unfertilized egg with the nucleus of a somatic cell is an nt ES (nuclear transfer ES) cell.
- nt ES nuclear transfer ES
- nuclear transfer technology JB Cibelli et al. (1998), Nature Biotechnol., 16: 642-646)
- ES cell production technology is used (Kiyaka Wakayama et al. ( 2008), Experimental Medicine, Vol.26, No.5 (extra number), pp. 47-52).
- Nuclear transfer can be initialized by injecting a somatic cell nucleus into a mammal's enucleated unfertilized egg and culturing for several hours.
- Multilineage-differentiating Stress Enduring cells are pluripotent stem cells produced by the method described in WO2011 / 007900. Specifically, fibroblasts or bone marrow stromal cells are treated with trypsin for a long time. Preferably, it is a pluripotent cell obtained by trypsin treatment for 8 hours or 16 hours and then suspension culture, and is positive for SSEA-3 and CD105.
- cardiomyocyte means a cell expressing at least cardiac troponin (cTnT) or ⁇ MHC.
- cTnT is exemplified by NCBI accession number NM_000364 for humans and NM_001130174 for mice.
- ⁇ MHC is exemplified by NCBI accession number NM_002471 for humans, and NM_001164171 for mice.
- the origin of the myocardial cells in the present invention is not particularly limited.
- the cells are contained in peripheral blood, heart, bone marrow tissue, adipose tissue, skeletal muscle tissue, amniotic tissue, placental tissue, umbilical cord blood and the like obtained by any method. It may also be a cell derived from a pluripotent stem cell.
- cardiomyocytes can be produced from pluripotent stem cells by, for example, the method reported by Laflamme MA et al. (Laflamme MA & Murry CE, Nature 2011, Review).
- a method of producing cardiomyocytes by forming a cell mass (embryoid body) by suspension culture of induced pluripotent stem cells, myocardium in the presence of a substance that suppresses BMP signaling A method for producing cells (WO2005 / 033298), a method for producing cardiomyocytes by sequentially adding Activin A and BMP (WO2007 / 002136), and producing cardiomyocytes in the presence of a substance that promotes activation of the canonical Wnt signaling pathway
- a method for isolating Flk / KDR positive cells from induced pluripotent stem cells and producing cardiomyocytes in the presence of cyclosporin A WO2009 / 118928.
- the method for inducing differentiation into cardiomyocytes is not particularly limited, and for example, the following method is used.
- Step (1) in the step of dissociating pluripotent stem cells, cells that are adhered to each other to form a population are dissociated (separated) into individual cells.
- a method of dissociating pluripotent stem cells for example, a method of dynamically dissociating, a dissociation solution having protease activity and collagenase activity (for example, Accutase (TM) and Accumax (TM), etc.) or dissociation having only collagenase activity Examples include a dissociation method using a solution.
- a method of dissociating pluripotent stem cells using a dissociation solution having protease activity and collagenase activity is used.
- dissociated pluripotent stem cells are artificially treated (for example, Matrigel (BD), collagen, Uses non-gelatin, laminin, heparan sulfate proteoglycan, or entactin coating, or artificially suppresses adhesion (for example, coating with polyhydroxyethyl methacrylic acid (poly-HEMA))
- the suspension culture is exemplified.
- the culture solution used in this step can be prepared by adding activin A, BMP4 and bFGF to the basal medium from the medium used for culturing animal cells.
- the basal medium include IMDM medium, Medium 199 medium, Eagle's Minimum Essential Medium (EMEM) medium, ⁇ MEM medium, Dulbecco's modified Eagle's Medium (DMEM) medium, Ham's F12 medium, RPMI 1640 medium, Fischer's medium, Neurobasal Medium (Life Technologies) ), StemPro34 (invitrogen) and mixed media thereof.
- the medium may contain serum or may be serum-free.
- the medium can be, for example, albumin, transferrin, Knockout Serum Replacement (KSR) (serum substitute for FBS during ES cell culture), N2 supplement (Invitrogen), B27 supplement (Invitrogen), fatty acid, insulin, collagen May contain one or more serum replacements such as precursors, trace elements, 2-mercaptoethanol, 1-thiolglycerol, lipids, amino acids, L-glutamine, Glutamax (Invitrogen), non-essential amino acids, vitamins, growth It may also contain one or more substances such as factors, low molecular weight compounds, antibiotics, antioxidants, pyruvate, buffers, inorganic salts and the like.
- a preferred basal medium is StemPro34 containing transferrin, 1-thiolglycerol, L-glutamine, ascorbic acid.
- the concentration of activin A used in this step is preferably 1 ng / ml to 100 ng / ml, 1 ng / ml, 2 ng / ml, 3 ng / ml, 4 ng / ml, 5 ng / ml, 6 ng / ml, 7 ng / ml, 8 ng / ml ml, 9ng / ml, 10ng / ml, 11ng / ml, 12ng / ml, 13ng / ml, 14ng / ml, 15ng / ml, 16ng / ml, 17ng / ml, 18ng / ml, 19ng / ml, 20ng / ml, Examples are 30 ng / ml, 40 ng / ml, 50 ng / ml, 60 ng / ml, 70 ng / ml, 80 ng /
- the concentration of BMP4 used in this step is preferably 1 ng / ml to 100 ng / ml, 1 ng / ml, 2 ng / ml, 3 ng / ml, 4 ng / ml, 5 ng / ml, 6 ng / ml, 7 ng / ml, 8 ng / ml 9ng / ml, 10ng / ml, 11ng / ml, 12ng / ml, 13ng / ml, 14ng / ml, 15ng / ml, 16ng / ml, 17ng / ml, 18ng / ml, 19ng / ml, 20ng / ml, 30ng Examples include / ml, 40 ng / ml, 50 ng / ml, 60 ng / ml, 70 ng / ml, 80 ng / ml, 90
- the concentration of bFGF used in this step is preferably 1 ng / ml to 100 ng / ml, 1 ng / ml, 2 ng / ml, 3 ng / ml, 4 ng / ml, 5 ng / ml, 6 ng / ml, 7 ng / ml, 8 ng / ml 9ng / ml, 10ng / ml, 11ng / ml, 12ng / ml, 13ng / ml, 14ng / ml, 15ng / ml, 16ng / ml, 17ng / ml, 18ng / ml, 19ng / ml, 20ng / ml, 30ng Examples include / ml, 40 ng / ml, 50 ng / ml, 60 ng / ml, 70 ng / ml, 80 ng / ml,
- the culture temperature is not limited to the following, but is about 30 to 40 ° C., preferably about 37 ° C., and it is desirable to carry out under low oxygen conditions.
- the low oxygen condition is a condition of an oxygen partial pressure lower than the oxygen partial pressure (20%) in the atmosphere, and examples thereof include an oxygen partial pressure of 1% to 15%. Examples are%, 8%, 7%, 6%, 5%, 4%, 3%, 2% and 1%. More preferably, it is 5%.
- Culturing is carried out in an atmosphere containing CO 2 and N 2 , the CO 2 concentration is preferably about 2-5%, and the N 2 concentration is preferably about 85-95%. In the present invention, it can be most preferably cultured under conditions of O 2 of 5%, CO 2 of 5%, and N 2 of 90%.
- the culture period is exemplified by 1 day or more and 7 days or less, and in consideration of the establishment efficiency of cardiomyocytes, it is exemplified by 1 day or more and 5 days or less, and 2 days or more and 4 days or less.
- the culture solution used in this step can be prepared by adding VEGF and a Wnt inhibitor to a basal medium from a medium used for animal cell culture.
- the basal medium include IMDM medium, Medium 199 medium, Eagle's Minimum Essential Medium (EMEM) medium, ⁇ MEM medium, Dulbecco's modified Eagle's Medium (DMEM) medium, Ham's F12 medium, RPMI 1640 medium, Fischer's medium, Neurobasal Medium (Life Technologies) ), StemPro34 (invitrogen) and mixed media thereof.
- the medium may contain serum or may be serum-free.
- the medium can be, for example, albumin, transferrin, Knockout Serum Replacement (KSR) (serum substitute for FBS during ES cell culture), N2 supplement (Invitrogen), B27 supplement (Invitrogen), fatty acid, insulin, collagen May contain one or more serum replacements such as precursors, trace elements, 2-mercaptoethanol, 1-thiolglycerol, lipids, amino acids, L-glutamine, Glutamax (Invitrogen), non-essential amino acids, vitamins, growth It may also contain one or more substances such as factors, low molecular weight compounds, antibiotics, antioxidants, pyruvate, buffers, inorganic salts and the like.
- a preferred basal medium is StemPro34 containing transferrin, 1-thiolglycerol, L-glutamine, ascorbic acid.
- a Wnt inhibitor is a substance that inhibits signal transduction from binding of Wnt to a receptor to accumulation of ⁇ -catenin, a substance that inhibits binding to the receptor Frizzled family, or ⁇
- the substance is not particularly limited as long as it is a substance that promotes the degradation of catenin.
- DKK1 protein for example, NCBI accession number: NM_012242 for humans
- sclerostin for example, NCBI accession number for humans: NM_025237
- IWR-1 Merck Millipore
- IWP-2 Sigma-Aldrich
- IWP-3 Sigma-Aldrich
- IWP-4 Sigma-Aldrich
- PNU-74654 Sigma-Aldrich
- XAV939 Sigma- Aldrich
- the Wnt inhibitor used in this step can be preferably IWP-3 or IWP-4.
- the concentration of a Wnt inhibitor such as IWP-3 or IWP-4 in the culture solution is not particularly limited as long as it is a concentration that inhibits Wnt, but is preferably 1 nM to 50 ⁇ M, for example, 1 nM, 10 nM, 50 nM, 100 nM, 500 nM, 750 nM, 1 ⁇ M, 2 ⁇ M, 3 ⁇ M, 4 ⁇ M, 5 ⁇ M, 6 ⁇ M, 7 ⁇ M, 8 ⁇ M, 9 ⁇ M, 10 ⁇ M, 15 ⁇ M, 20 ⁇ M, 25 ⁇ M, 30 ⁇ M, 40 ⁇ M, 50 ⁇ M, but are not limited thereto. More preferably, it is 1 ⁇ M.
- the concentration of VEGF used in this step is preferably 1 to 100 ng / ml, 1 ng / ml, 2 ng / ml, 3 ng / ml, 4 ng / ml, 5 ng / ml, 6 ng / ml, 7 ng / ml, 8 ng / ml, 9ng / ml, 10ng / ml, 11ng / ml, 12ng / ml, 13ng / ml, 14ng / ml, 15ng / ml, 16ng / ml, 17ng / ml, 18ng / ml, 19ng / ml, 20ng / ml, 30ng / Examples include ml, 40 ng / ml, 50 ng / ml, 60 ng / ml, 70 ng / ml, 80 ng / ml, 90 ng / m
- the culture temperature is not limited to the following, but is about 30 to 40 ° C., preferably about 37 ° C., and it is desirable to carry out under low oxygen conditions.
- the low oxygen condition is a condition of an oxygen partial pressure lower than the oxygen partial pressure (20%) in the atmosphere, and examples thereof include an oxygen partial pressure of 1% to 15%. Examples are%, 8%, 7%, 6%, 5%, 4%, 3%, 2% and 1%. More preferably, it is 5%.
- Cultivation is performed in an atmosphere containing CO 2 and N 2 , the CO 2 concentration is preferably about 2-5%, and the N2 concentration is preferably about 85-95%. In the present invention, it can be most preferably cultured under conditions of O 2 of 5%, CO 2 of 5%, and N 2 of 90%.
- the culture period does not affect the establishment of cardiomyocytes by culturing for a long period of time, there is no particular upper limit, but it is preferable to culture for 4 days or more.
- the 4th, 5th, 6th, 7th, 8th, 9th and 10th may be mentioned.
- the culture solution used in this step can be prepared by adding VEGF and bFGF to a basal medium from a medium used for animal cell culture.
- the basal medium include IMDM medium, Medium 199 medium, Eagle's Minimum Essential Medium (EMEM) medium, ⁇ MEM medium, Dulbecco's modified Eagle's Medium (DMEM) medium, Ham's F12 medium, RPMI 1640 medium, Fischer's medium, Neurobasal Medium (Life Technologies) ), StemPro34 (invitrogen) and mixed media thereof.
- the medium may contain serum or may be serum-free.
- the medium can be, for example, albumin, transferrin, Knockout Serum Replacement (KSR) (serum substitute for FBS during ES cell culture), N2 supplement (Invitrogen), B27 supplement (Invitrogen), fatty acid, insulin, collagen May contain one or more serum replacements such as precursors, trace elements, 2-mercaptoethanol, 1-thiolglycerol, lipids, amino acids, L-glutamine, Glutamax (Invitrogen), non-essential amino acids, vitamins, growth It may also contain one or more substances such as factors, low molecular weight compounds, antibiotics, antioxidants, pyruvate, buffers, inorganic salts and the like.
- a preferred basal medium is StemPro34 containing transferrin, 1-thiolglycerol, L-glutamine, ascorbic acid.
- the concentration of VEGF used in this step is preferably 1 to 100 ng / ml, 1 ng / ml, 2 ng / ml, 3 ng / ml, 4 ng / ml, 5 ng / ml, 6 ng / ml, 7 ng / ml, 8 ng / ml, 9 ng / ml, 10ng / ml, 11ng / ml, 12ng / ml, 13ng / ml, 14ng / ml, 15ng / ml, 16ng / ml, 17ng / ml, 18ng / ml, 19ng / ml, 20ng / ml, 30ng / ml 40 ng / ml, 50 ng / ml, 60 ng / ml, 70 ng / ml, 80 ng / ml, 90 ng / ml and
- the concentration of bFGF used in this step is preferably 1 to 100 ng / ml, 1 ng / ml, 2 ng / ml, 3 ng / ml, 4 ng / ml, 5 ng / ml, 6 ng / ml, 7 ng / ml, 8 ng / ml, 9 ng / ml, 10ng / ml, 11ng / ml, 12ng / ml, 13ng / ml, 14ng / ml, 15ng / ml, 16ng / ml, 17ng / ml, 18ng / ml, 19ng / ml, 20ng / ml, 30ng / ml 40 ng / ml, 50 ng / ml, 60 ng / ml, 70 ng / ml, 80 ng / ml, 90 ng / ml
- the culture temperature is not limited to the following, but may be about 30-40 ° C., preferably about 37 ° C.
- the low oxygen condition is a condition of an oxygen partial pressure lower than the oxygen partial pressure in the atmosphere (20%).
- an oxygen partial pressure between 1% and 15% can be mentioned. Examples are%, 8%, 7%, 6%, 5%, 4%, 3%, 2% and 1%. More preferably, it is 5%.
- the partial pressure of oxygen may be performed in the middle of the step at the same level as in the atmosphere.
- the upper limit is not particularly set because there is no change in the induction efficiency of cardiomyocytes, particularly when performed under hypoxic conditions.
- the initial period of the step is cultured under conditions of 5% O 2 , 5% CO 2 and 90% N 2 , and the subsequent period is under an atmosphere containing 5% CO 2. Culture is performed.
- the culture period does not affect the establishment of cardiomyocytes by culturing for a long time, there is no particular upper limit, but it is preferable to culture for 12 days or longer.
- 8th, 9th, 10th, 11th, 12th, 13th, 14th, 15th, 16th, 17th, 18th, 19th, 20th, 21st, 22nd or more Can be mentioned.
- the miRNA-responsive mRNA introduced into the cell group is preferably a cell group that has undergone a step of inducing differentiation from pluripotent stem cells to cardiomyocytes.
- the time when miRNA-responsive mRNA is introduced into a cell group that has undergone a differentiation-inducing step from pluripotent stem cells is not particularly limited as long as it is a time when cell selection is desired.
- the step of inducing differentiation using the method described in detail in the above-mentioned myocardial differentiation inducing method it is preferably 10 to 25 days from the embryoid body, more preferably 18 days. is there.
- the miRNA-responsive mRNA introduced into the cell group includes (i) a nucleic acid specifically recognized by miRNA specifically expressed in cardiomyocytes, and (ii) a sequence containing a nucleic acid corresponding to the coding region of the gene And the translation of the nucleic acid corresponding to the coding region of the gene (ii) into a protein is controlled by the nucleic acid sequence (i).
- the miRNA-responsive mRNA comprising a sequence containing (i) and (ii) is preferably a sequence specifically recognized by miRNA expressed specifically in cardiomyocytes (hereinafter referred to as miRNA target sequence).
- miRNA target sequence a sequence specifically recognized by miRNA expressed specifically in cardiomyocytes.
- the translation of the nucleic acid corresponding to the coding region of the gene of (ii) into a protein is controlled by the nucleic acid sequence of (i) when there is miRNA specifically expressed in cardiomyocytes. This means that the translation of a nucleic acid corresponding to the coding region of a gene into a protein is controlled in accordance with the abundance.
- the translation of the nucleic acid corresponding to the coding region of the gene of (ii) is suppressed according to the abundance thereof, so that (ii ) In which the amount of protein translated from the nucleic acid corresponding to the coding region of the gene is reduced.
- miRNA-responsive mRNA that functions so that translation into a protein is suppressed in accordance with the abundance of miRNA molecules that specifically bind to the miRNA target sequence, miRNA-responsive offswitch mRNA Referred to. That is, when miRNA-responsive off-switch mRNA is used, cells with a smaller translation amount of the gene (ii) contained in the mRNA can be selected as cardiomyocytes.
- the “miRNA” in the present invention is a short non-coding RNA (20-25 bases) existing in cells involved in regulation of gene expression through inhibition of translation from mRNA to protein and degradation of mRNA. .
- This miRNA is transcribed from DNA as a single difference pri-miRNA capable of taking a hairpin loop structure including miRNA and its complementary strand, and partly cleaved by an enzyme called Drosha in the nucleus. After being transported out of the nucleus, it is further cleaved by Dicer and functions.
- miRNA specifically expressed in cardiomyocytes used in the present invention is particularly a miRNA that is highly expressed in cardiomyocytes compared to cells other than cardiomyocytes. It is not limited. For example, 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more in cardiomyocytes compared to cells other than cardiomyocytes Alternatively, it may be miRNA highly expressed at a higher rate, but is not limited thereto.
- miRNAs are listed in database information (for example, http://www.mirbase.org/ or http://www.microrna.org/) and / or described in the database. It can select suitably from miRNA described in literature information.
- the “miRNA specifically expressed in cardiomyocytes” in the above (i) is preferably miR-1, miR-143-3p, miR-208a, miR-208b and miR-499a-5p. It can be.
- the above-mentioned (i) “specifically recognized by miRNA expressed specifically in cardiomyocytes” means that the miRNA interacts with a predetermined plurality of proteins, and RNA-inducedsilencing. It means that miRNA exists in a complex (RISC) formation state.
- RISC complex
- the target sequence of miRNA is preferably, for example, a sequence that is completely complementary to the miRNA.
- the miRNA target sequence may have a mismatch (mismatch) with a completely complementary sequence as long as it can be recognized in the miRNA.
- the mismatch from the sequence that is completely complementary to the miRNA may be any mismatch that can be normally recognized by the miRNA in the desired cell, and the mismatch of about 40 to 50% in the original function in the cell in vivo. There may be.
- Such mismatch is not particularly limited, but 1 base, 2 bases, 3 bases, 4 bases, 5 bases, 6 bases, 7 bases, 8 bases, 9 bases, or 10 bases or 1% of the total recognition sequence, 5% %, 10%, 20%, 30%, or 40% discrepancy.
- a region may contain a number of mismatches, and portions of the seed region may contain no mismatches, or may contain 1 base, 2 bases, or 3 bases mismatches.
- Such a sequence may be a base length including the number of bases to which the RISC specifically binds, and the length is not particularly limited, but is preferably a sequence of 18 bases or more and less than 24 bases, more preferably It is a sequence of 20 bases or more and less than 22 bases.
- the miRNA target sequence introduces miRNA-responsive mRNA having the sequence into cardiomyocytes and cells other than cardiomyocytes, and confirms that the expression of the corresponding marker gene is suppressed only in cardiomyocytes. Can be appropriately determined and used.
- preferred miRNA target sequences corresponding to “miRNA specifically expressed in cardiomyocytes” are exemplified in Table 2.
- nucleic acid corresponding to the coding region of a gene used in the present invention is a nucleic acid gene that encodes an arbitrary protein that is translated in a cell and enables the selection of cardiomyocytes.
- the “gene” may be a marker gene.
- a “marker gene” is a gene that is translated in a cell, functions as a marker, and encodes an arbitrary protein that enables the selection of cardiomyocytes. Examples of proteins that can be translated into cells and function as markers include, for example, visualization, quantification by assisting fluorescence, luminescence, coloration, or fluorescence, luminescence, or coloration of fluorescence, fluorescent proteins, etc.
- a gene that encodes a protein that can be activated a membrane protein, or a gene that encodes a protein that kills a cell when expressed, such as an apoptosis-inducing gene or a suicide gene.
- an apoptosis-inhibiting gene can also be used as a marker gene.
- a protein translated from mRNA containing a nucleic acid corresponding to the coding region of the marker gene is referred to as a marker protein.
- fluorescent proteins include blue fluorescent proteins such as Sirius, BFP, and EBFP; cyan fluorescent proteins such as mTurquoise, TagCFP, AmCyan, mTFP1, MidoriishiCyan, and CFP; TurboGFP, AcGFP, TagGFP, Azami-Green (for example, hmAG1 ), Green fluorescent proteins such as ZsGreen, EmGFP, EGFP, GFP2, HyPer; yellow fluorescent proteins such as TagYFP, EYFP, Venus, YFP, PhiYFP, PhiYFP-m, TurboYFP, ZsYellow, mBanana; KusabiraOrange (for example, hmKO2), mOrange Orange fluorescent proteins such as: TurboRFP, DsRed-Express, DsRed2, TagRFP, DsRed-Monomer, AsRed2, mStrawberry and other red fluorescent proteins; TurboFP602, mRFP1, JRed, KillerRed, mCh
- the photoprotein can be exemplified by aequorin, but is not limited thereto.
- proteins that assist fluorescence, luminescence, or coloration include, but are not limited to, enzymes that degrade fluorescence, luminescence, or color precursors such as luciferase, phosphatase, peroxidase, and ⁇ -lactamase.
- a substance that assists fluorescence, luminescence, or color is used as a marker gene
- the corresponding precursor is brought into contact with the cell group , or the corresponding precursor in the cell group. This can be done by introducing a substance.
- the apoptosis-inducing gene means a gene encoding a protein having apoptosis-inducing activity for cells.
- Bim is preferably used as an apoptosis-inducing gene.
- the suicide gene means a gene whose expression in a cell is lethal to the cell.
- the suicide gene may be one that causes cell death by itself (eg, diphtheria A toxin) or the expression of this gene sensitizes the cell to a specific drug (eg, Or sensitize cells to antiviral compounds by expression of the herpes simplex thymidine kinase gene).
- suicide genes include diphtheria A toxin, herpes simplex thymidine kinase gene (HSV-TK), carboxypeptidase G2 (CPG2), carboxylesterase (CA), cytosine deaminase (CD), cytochrome P450 (cyt-450), deoxycytidine Genes encoding kinase (dCK), nitroreductase (NR), purine nucleoside phosphorylase (PNP), thymidine phosphorylase (TP), varicella-zoster virus thymidine kinase (VZV-TK), xanthine-guanine phosphoribosyltransferase (XGPRT), etc.
- HSV-TK is preferably used as a suicide gene.
- the marker gene may include a gene encoding a localization signal.
- the localization signal include a nuclear localization signal, a cell membrane localization signal, a mitochondrial localization signal, a protein secretion signal, and the like.
- a classical nuclear translocation sequence (NLS), M9 Examples include, but are not limited to, sequences, mitochondrial target sequences (MTS), and endoplasmic reticulum translocation sequences.
- Such a localization signal is particularly advantageous when a screening step in a method for producing cardiomyocytes described later is performed on an image by imaging cytometry described later.
- the miRNA target sequence and the marker gene are functionally linked to each other in the 5′UTR, 3′UTR of the open reading frame (including the start codon) encoding the marker gene, and Means comprising at least one miRNA target sequence within the open reading frame.
- the miRNA-responsive mRNA preferably comprises a Cap structure (7-methylguanosine 5′-phosphate), an open reading frame encoding a marker gene, and a poly A tail in the direction 5 ′ to 3 ′ from the 5 ′ end. It comprises at least one miRNA target sequence in the 5′UTR, in the 3′UTR, and / or in the open reading frame.
- the position of the target sequence of miRNA in mRNA may be 5′UTR or 3′UTR, may be within the open reading frame (3 ′ side of the start codon), and all of these include miRNA
- the target sequence may be provided.
- the number of miRNA target sequences may be one, two, three, four, five, six, seven, eight or more.
- the nucleic acids (i) and (ii) are linked in this order in the 5 ′ to 3 ′ direction. Therefore, only one miRNA target sequence needs to be present in the 5 'UTR. This is because efficient translation suppression can be achieved.
- the number of bases and the kind of base between the cap structure and the target sequence of miRNA may be arbitrary as long as they do not constitute a stem structure or a three-dimensional structure.
- the number of bases between the cap structure and the miRNA target sequence can be designed to be 0 to 50 bases, preferably 10 to 30 bases.
- the number of bases and the type of base between the miRNA target sequence and the start codon may be arbitrary as long as they do not constitute a stem structure or a three-dimensional structure, and the number of bases between the miRNA target sequence and the start codon is 0. It can be designed with an arrangement of -50 bases, preferably 10-30 bases.
- an AUG serving as an initiation codon does not exist in the miRNA target sequence in the miRNA-responsive mRNA.
- the target sequence of miRNA is present in the 5′UTR and AUG is included in the target sequence, it is designed to be in-frame in relation to the marker gene linked to the 3 ′ side. It is preferable.
- AUG in the target sequence can be converted to GUG and used.
- the location of the target sequence in the 5′UTR can be changed as appropriate.
- the number of bases between the cap structure and the AUG sequence in the target sequence is 0 to 60 bases, for example, 0 to 15 bases, 10 to 20 bases, 20 to 30 bases, 30 to 40 bases, 40 to 50 bases , Can be designed in an arrangement of 50 to 60 bases.
- the mRNA preferably contains a modified base such as pseudouridine or 5-methylcytidine instead of ordinary uridine and cytidine. This is to reduce cytotoxicity.
- the positions of the modified bases can be all or part of the uridine and cytidine independently, and if they are part of the base, they can be random positions at an arbitrary ratio.
- the target sequence of miRNA when the target sequence of miRNA is present in the 5'UTR, for example, the following sequences can be employed.
- the target sequence of miRNA when the target sequence of miRNA is present in the 5'UTR, the following sequence can be adopted, for example, downstream of the marker gene that follows (ie, the 3'UTR). At this time, any gene as described above can be used as the marker gene sandwiched between the 5'UTR and the 3'UTR.
- the full length of the miRNA-responsive mRNA in the present invention is, for example, the following sequence for each miRNA specifically expressed in cardiomyocytes: Can be employed.
- a suicide gene for example, Bim
- the following sequences can be adopted as the miRNA-responsive mRNA in the present invention.
- the miRNA-responsive mRNA can be synthesized by those skilled in the art by any method known in genetic engineering if the sequence is determined according to the above. In particular, it can be obtained by an in vitro synthesis method using a template DNA containing a promoter sequence as a template.
- a screening step for examining the effectiveness of the selection may be performed. Specifically, a plurality of candidate miRNA-responsive mRNAs having a 5 ′ UTR as exemplified above are prepared, and each is introduced into a group of cardiomyocytes with known purity. High miRNA target sequences as well as miRNA-responsive mRNAs can be determined. Such a process is also described in detail in Example 3.
- miRNA-responsive mRNA Only one type of miRNA-responsive mRNA may be used, or two or more types, for example, 3, 4, 5, 6, 7, or 8 types may be used. For example, when two or more miRNA-responsive mRNAs are used, it is desirable that each miRNA-responsive mRNA is different for both the miRNA target sequence and the marker gene. When two or more miRNA-responsive mRNAs are used, the number of miRNA target sequences contained in the miRNA-responsive mRNA, the distance from the 5 ′ end of the miRNA target sequence, and other structural features of the miRNA-responsive mRNA are as follows: Each miRNA-responsive mRNA may be the same or different. Alternatively, it is also possible to use miRNA-responsive mRNAs that have the same miRNA target sequence but different marker genes.
- an apoptosis-inducing gene that transmits signals through different pathways, for example, miRNA-responsive mRNA in which Fas and Bim are combined with the same miRNA target sequence. It can be expected to efficiently remove cells other than cells.
- mRNA containing BFP as exemplified in Table 5 as a marker gene and mRNA containing Keima-Red as exemplified in Table 7 below as a marker gene are used.
- BFP as exemplified in Table 5
- Keima-Red as exemplified in Table 7 below
- the step of introducing miRNA-responsive mRNA into a cell group is performed using a lipofection method, a liposome method, an electroporation method, a calcium phosphate coprecipitation method, a DEAE dextran method, a microinjection method, a gene gun method, etc. More than one species of miRNA-responsive mRNA is directly introduced into cells included in the cell group. When two or more different miRNA-responsive mRNAs are introduced, or when miRNA-responsive mRNA and a control mRNA (hereinafter also referred to as control mRNA) are used, a plurality of mRNAs are added to a cell group. Co-introduction is preferred.
- the introduction amount at this time varies depending on the cell group to be introduced, the mRNA to be introduced, the introduction method and the kind of the introduction reagent, and those skilled in the art can appropriately select these in order to obtain a desired translation amount.
- control mRNA is mRNA consisting of a sequence containing a nucleic acid corresponding to the coding region of a marker gene or a sequence containing a nucleic acid corresponding to the coding region of a drug resistance gene, and does not have a miRNA target site.
- An example is mRNA.
- the control mRNA is introduced into a cell group together with the miRNA-responsive mRNA, and can function as a control for confirming and identifying the cell into which the miRNA-responsive mRNA has been introduced. Moreover, it can function as a control in quantifying signal intensity such as fluorescence and luminescence from miRNA-responsive mRNA.
- the amount of control mRNA introduced can also be appropriately selected by those skilled in the art to obtain a desired translation amount.
- the “drug resistance gene” used in the present invention may be any gene as long as it expresses a protein having resistance to the corresponding drug.
- examples include, but are not limited to, antibiotic resistance genes.
- antibiotic resistance genes include kanamycin resistance gene, ampicillin resistance gene, puromycin resistance gene, blasticidin resistance gene, gentamicin resistance gene, kanamycin resistance gene, tetracycline resistance gene, chloramphenicol resistance gene, etc.
- a puromycin resistance gene or a blasticidin resistance gene is used as the antibiotic resistance gene.
- the selection method preferably includes a step of simultaneously introducing miRNA-responsive mRNA and control mRNA into a cell group including cardiomyocytes. Such a step can be preferably carried out by co-introduction of miRNA-responsive mRNA and control mRNA.
- control mRNA By using control mRNA, cells with low or non-translated marker protein translated from miRNA-responsive mRNA can be selected as cardiomyocytes even when the efficiency of miRNA-responsive mRNA introduction into cells is low. .
- the marker gene contained in the control mRNA is preferably different from the marker gene contained in the miRNA-responsive mRNA.
- the marker gene contained in miRNA-responsive mRNA is an apoptosis-inducing gene or a suicide gene
- the marker gene contained in the control mRNA can be a gene encoding a fluorescent protein.
- a control mRNA comprising a sequence containing a nucleic acid corresponding to the coding region of a drug resistance gene can be used together with an miRNA-responsive mRNA comprising a sequence containing a nucleic acid corresponding to the coding region of any marker gene.
- an miRNA-responsive mRNA comprising a sequence containing a nucleic acid corresponding to the coding region of any marker gene.
- the same gene may be used for both the marker gene contained in miRNA-responsive mRNA and the marker gene contained in control mRNA.
- a gene encoding a fluorescent protein may be used for both the marker gene contained in the miRNA-responsive mRNA and the marker gene contained in the control mRNA.
- the fluorescence wavelengths of the two fluorescent proteins are different. It is desirable.
- a photoprotein or a gene encoding a protein that assists fluorescence, luminescence, or coloration can be used in the same combination.
- control mRNA in the present invention is not particularly limited.
- the following mRNAs can be used.
- the step of introducing miRNA-responsive mRNA and optionally control mRNA into the cell group is carried out, so that the myocardium can be detected from the cell group that can contain cardiomyocytes.
- Cells can be sorted. That is, it is possible to make a state in which detectable signal information different from other cell types is presented for a desired cardiomyocyte out of a cell group including two or more types of cells that can contain cardiomyocytes.
- the cardiomyocytes can be selectively separated by further carrying out the sorting step by the production method described later.
- the present invention is a method for producing cardiomyocytes, which comprises the following: (a) introducing miRNA-responsive mRNA into a cell population, and (b) including the step of selecting the cardiomyocytes based on the amount of protein translated from the miRNA-responsive mRNA of step (a),
- the miRNA-responsive mRNA is: (i) a nucleic acid specifically recognized by miRNA specifically expressed in cardiomyocytes, and (ii) consisting of a sequence comprising a nucleic acid corresponding to the coding region of the gene,
- a method capable of recovering highly pure cardiomyocytes as compared with the case where the above steps (a) and (b) are not performed. Cardiomyocytes can be recovered by selecting cells with a smaller translation amount of the gene (ii) contained in the miRNA-responsive mRNA.
- step (a) can be carried out in the same manner as the introduction step described in the above-described method for selecting cardiomyocytes. Therefore, the miRNA target sequence of (i) in the configuration of miRNA-responsive mRNA is the same as described above.
- a control mRNA having a gene encoding a fluorescent protein as a marker gene is co-introduced with an miRNA-responsive mRNA, or a gene encoding a fluorescent protein having a different fluorescence wavelength is used as a marker gene.
- Two or more miRNA-responsive mRNAs are co-introduced. Thereby, the amount of the protein translated from the miRNA-responsive mRNA can be obtained more accurately.
- the “gene” of (ii) used in the present invention may be the same marker gene as described above.
- a gene encoding a fluorescent protein is used.
- the fluorescent protein is also as described above.
- a gene encoding BFP is used as a gene encoding the fluorescent protein.
- the cell group in the step (a) used in the present invention may be an arbitrary cell group, for example, a cell group induced to differentiate from a pluripotent stem cell, or a cell group removed from the living body. It may be a group.
- a cell group that has undergone a step of inducing differentiation from pluripotent stem cells to cardiomyocytes is preferable.
- the time when miRNA-responsive mRNA is introduced into a cell group that has undergone a differentiation-inducing step from pluripotent stem cells is not particularly limited as long as it is a time when cell selection is desired.
- the step of inducing differentiation using the method described in detail in the above-mentioned myocardial differentiation inducing method is performed, it is preferably 10 to 25 days from the embryoid body, more preferably 18 days. is there.
- cardiomyocytes can be selected using the amount of marker protein translated from miRNA-responsive mRNA as an index. That is, it can be a step of selecting a cell in which the amount of marker protein translated from miRNA-responsive mRNA is small or undetectable. Such a cell with a low miRNA expression level can be determined by comparing the translation amount of the marker protein with cells other than cardiomyocytes.
- the selection step can be performed by detecting a signal from a marker protein, which is a translation product from a marker gene, using a predetermined detection device.
- the detection device include, but are not limited to, a flow cytometer, an imaging cytometer, a fluorescence microscope, a light emission microscope, and a CCD camera.
- a detection apparatus those suitable for those skilled in the art can be used depending on the marker protein.
- the marker when it is a fluorescent protein or a luminescent protein, it can be selected using a flow cytometer, and when the marker is a protein that assists fluorescence, luminescence or coloration, using a microscope, Using a culture dish coated with photo-responsive cell culture equipment, light can be applied to colored cells, and the cells that have not been irradiated can be separated from the culture dish and sorted.
- a cell surface protein-specific detection reagent such as an antibody and a marker protein quantification method using the above-described detection device are possible, and a magnetic cell separation device (MACS) It is possible to isolate cells without the marker protein quantification process, and when the marker protein is a drug resistance gene, By detecting the expression of genes, it is possible method of isolating live cells.
- the cardiomyocytes obtained in the production method of the present invention can be obtained with a purity higher than that obtained by a normal differentiation induction method that has not undergone a step of sorting using miRNA-responsive mRNA.
- the purity of cardiomyocytes is not particularly limited as long as it is high purity as compared with the case where it does not go through the step of selecting using miRNA-responsive mRNA, preferably 60% or more, 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95% 96%, 97%, 98%, 99% and 100%.
- the purity in this case is a value obtained using TNT specifically expressed in cardiomyocytes as an index.
- it can be carried out by labeling TNT with a substance that can be detected by a sorting device such as flow cytometry on a cell group to be sorted.
- the substance that can be detected by the sorting device is not particularly limited, and examples thereof include a combination of a primary antibody and a secondary antibody.
- purity confirmation using TNT as an indicator is performed by fixing a cell group to be sorted with paraformaldehyde, then providing a primary antibody against TNT, and then a secondary containing a substance that can be detected by a sorting device. This is done by applying an antibody.
- clone 13-11 (Thermo) is used as the primary antibody against TNT, and APC goat anti-mouse Ig (BD pharmingen) is used as the secondary antibody.
- the purity can be obtained by applying it to a sorting device such as flow cytometry.
- the present invention is a method for producing cardiomyocytes, which comprises the following: (a) introducing an mRNA comprising a sequence containing a miRNA-responsive mRNA and a nucleic acid corresponding to a coding region of a drug resistance gene into a cell group ; and (b) culturing the cell population obtained in step (a) in the presence of a drug corresponding to the drug resistance gene in step (a),
- the miRNA-responsive mRNA is: (i) a nucleic acid specifically recognized by miRNA specifically expressed in cardiomyocytes, and (ii) consisting of a sequence comprising a nucleic acid corresponding to the coding region of the gene,
- a method capable of recovering highly pure cardiomyocytes as compared with the case where the above steps (a) and (b) are not performed.
- step (a) can be carried out in the same manner as the introduction step described in the above-described method for selecting cardiomyocytes. Therefore, the miRNA target sequence of (i) in the structure of miRNA-responsive mRNA can be the same as described above.
- the “gene” of (ii) used in this embodiment may be the same marker gene as described above, and preferably an apoptosis-inducing gene or a suicide gene is used.
- the apoptosis-inducing gene and the suicide gene are also as described above.
- Bim is used as the apoptosis-inducing gene and HSV-TK is used as the suicide gene.
- the “drug resistance gene” used in the present invention is the same as described above, and preferably a puromycin resistance gene or a blasticidin resistance gene is used.
- MRNA consisting of a sequence containing a nucleic acid corresponding to the coding region of a drug resistance gene is a control mRNA having no miRNA target sequence.
- the mRNA comprising the sequence containing the miRNA-responsive mRNA and the nucleic acid corresponding to the coding region of the drug resistance gene is preferably co-introduced into the cell group.
- the cell group in the step (a) used in the present embodiment may be the same as the cell group in the step (a) in the cardiomyocyte production method (1).
- the concentration of the drug resistance gene in step (a) and the corresponding drug in step (b) used in the present invention is such that cells that do not have the drug resistance gene survive when cultured in the presence of the corresponding drug. Any concentration that can not be used can be adopted.
- the concentration of the control mRNA to be co-introduced is preferably 1 to 40 ng / ml, and 1 ng / ml, 2 ng / ml, 3 ng / ml, 4 ng / ml, 5 ng / ml ml, 6ng / ml, 7ng / ml, 8ng / ml, 9ng / ml, 10ng / ml, 11ng / ml, 12ng / ml, 13ng / ml, 14ng / ml, 15ng / ml, 16ng / ml, 17ng / ml,
- the concentration of puromycin added to the medium is preferably 1 to 40 ⁇ g / ml, and is 1 ⁇ g / ml, 2 ⁇ g / ml, 3 ⁇ g / ml, 4 ⁇ g / ml, 5 ⁇ g / ml, 6 ⁇ g / ml, 7 ⁇ g / ml.
- kits for selecting or producing cardiomyocytes with high purity can be a kit containing miRNA-responsive mRNA.
- the miRNA-responsive mRNA included in the kit of the present invention is not particularly limited, but preferably an miRNA-responsive off-switch mRNA is used.
- the specific configuration of miRNA-responsive mRNA is as described in the cardiomyocyte screening method and cardiomyocyte production method.
- the kit of the present invention may include the miRNA-responsive mRNA described in these methods, as well as all combinations of a plurality of miRNA-responsive mRNAs.
- the kit of the present invention may further contain a control mRNA.
- a control mRNA When a control mRNA is included, a preferable combination of miRNA-responsive mRNA and control mRNA is as described in the above-described method for selecting cardiomyocytes.
- the kit of the present invention may contain all the combinations of miRNA-responsive mRNA and a plurality of miRNA-responsive mRNAs and control mRNAs described in the cardiomyocyte sorting method and cardiomyocyte production method.
- the kit for carrying out the method (2) for producing cardiomyocytes comprises a control mRNA consisting of a sequence containing a nucleic acid corresponding to the coding region of the drug resistance gene.
- the kit in the present invention may contain a reagent for introducing the mRNA together with the miRNA-responsive mRNA.
- reagents necessary for cardiomyocyte purification and instructions for carrying out the selection method or the production method of the present invention can be included as appropriate.
- the cell group to be used in the kit of the present invention may be the same as the cell group described in the above-described cardiomyocyte selection method and cardiomyocyte production method, and is a cell induced to differentiate from a pluripotent stem cell. It may be a group of cells taken out from the living body.
- the kit in the present invention can be used for selecting cardiomyocytes from a population in which a plurality of cells are mixed, and can also be used for confirming the purity of cardiomyocytes in a certain cell population.
- the method for producing and using the miRNA-responsive mRNA and optionally the control mRNA included in the kit are as described in the above-described cardiomyocyte sorting method and cardiomyocyte production method.
- the cardiomyocytes obtained in the present invention can be obtained from the group of cells containing the cardiomyocytes obtained in the sorting step as they are, or optionally, in a conventional manner, with the cardiomyocytes obtained in the sorting step intact. It can be used as a therapeutic agent for heart diseases in animals (preferably humans) through a process of removing dead cells and contaminants.
- the obtained myocardial cells may be suspended in physiological saline and administered directly to the myocardium of the heart, or the obtained myocardial cells may be formed into a sheet and the patient's heart It may be performed by sticking to.
- a myocardial sheet When a myocardial sheet is administered, it is achieved by placing it so as to cover a desired portion.
- the arrangement so as to cover a desired portion can be performed using a technique well known in the art. In the case of placement, if the desired part is large, it may be placed so as to surround the tissue. In addition, administration can be performed several times on the same part in order to obtain a desired effect.
- the mechanism of treatment of such heart diseases may be the effect caused by the engraftment of the myocardial sheet, or an indirect action that does not depend on the engraftment of cells (for example, recipients by secreting attractants). Effect of mobilization of the derived cells to the damaged site).
- a myocardial sheet when using a myocardial sheet, it may contain a cell scaffold material (scaffold) such as collagen, fibronectin, laminin and the like in addition to the myocardial cells.
- a cell scaffold material such as collagen, fibronectin, laminin and the like in addition to the myocardial cells.
- any cell type (s) may be included.
- Heart diseases that can be treated in the present invention include heart failure, ischemic heart disease, myocardial infarction, cardiomyopathy, myocarditis, hypertrophic cardiomyopathy, dilated phase hypertrophic cardiomyopathy, deficiency due to dilated cardiomyopathy, etc. However, it is not limited to these.
- the number of cardiomyocytes used for the treatment of heart disease is not particularly limited as long as the administered cardiomyocytes or myocardial sheet is an amount that exerts an effect in the treatment of heart disease, It may be prepared by appropriately increasing or decreasing according to the size of the affected part or the size of the body.
- Example 1 The following strains were used as the pluripotent stem cell strain 201B7 (Takahashi K, et al. Cell. 131: 861-72, 2007), 409B2 strain, 947A2 strain, and KhES1 strain.
- the 201B7 strain was prepared by the method described in Takahashi K, et al. Cell. 131: 861-72, 2007.
- Episomal vectors (pCXLE-hOCT3 / 4-shp53-F, pCXLE-hSK, pCXLE -hUL) was transfected by electroporation and cultured on a mitomycin-treated mouse fetal fibroblast feeder to prepare an iPS cell line. Culture was performed by conventional methods (Takahashi K, et al. Cell. 131: 861-72, 2007 and Nakagawa M, et al. Nat Biotechnol. 26: 101-6, 2008). (3) 947A2 strain An iPS cell strain was prepared from human peripheral blood cells using the same method as in the above-mentioned 409B2 strain.
- the culture was also performed in the same manner as for the above-mentioned 409B2 strain.
- KhES1 strain Human ES cells were cultured by a conventional method using the KhES1 strain established by the Research Center for Stem Cell Medicine, Institute of Regenerative Medicine, Kyoto University (Suemori H, et al. Biochem Biophys Res Commun. 345). : 926-32, 2006).
- Cardiomyocyte induction method 201B7, 409B2, 947A2 or KhES1 is treated with CTK solution (ReproCELL) for 2 minutes, then the solution is removed, then treated with Accumax (Innovative Cell Technologies) for 5 minutes, and then pipetting Dissociated into single cells.
- CTK solution ReproCELL
- Accumax Innovative Cell Technologies
- Cells are collected by centrifugation and transferred to a low adhesion 6 well dish (Corning), 2 mM L-Glutamine, 150 ⁇ g / mL Transferrin, 50 ⁇ g / mL Ascorbic Acid (sigma), 4 ⁇ 10 ⁇ 4 M monothioglycerol (MTG) and 2 ng EBs were formed by culturing in 1.5 ml / well STEMPRO 34 (Invitrogen) supplemented with / mL BMP4 (R & D) at 37 ° C. under 5% oxygen condition (day 0).
- STEMPRO 34 Invitrogen
- BMP4 R & D
- the obtained EB was washed with IMDM (Invitrogen), 1% L-Glutamine, 150 ⁇ g / mL Transferrin, 50 ⁇ g / mL Ascorbic Acid, 4 ⁇ 10 ⁇ 4 M MTG, 10 ng / mL VEGF and STEMPRO 34 supplemented with 1 ⁇ M IWP-3 was added to the dish and cultured at 37 ° C. under 5% oxygen for 4 days.
- IMDM Invitrogen
- 1% L-Glutamine 150 ⁇ g / mL Transferrin
- 50 ⁇ g / mL Ascorbic Acid 50 ⁇ g / mL Ascorbic Acid
- 4 ⁇ 10 ⁇ 4 M MTG 10 ng / mL VEGF and STEMPRO 34 supplemented with 1 ⁇ M IWP-3 was added to the dish and cultured at 37 ° C. under 5% oxygen for 4 days.
- the medium was replaced with STEMPRO 34 supplemented with 1% L-Glutamine, 150 ⁇ g / mL Transferrin, 50 ⁇ g / mL Ascorbic Acid, 4 ⁇ 10 ⁇ 4 M MTG, 10 ng / mL VEGF and 5 ng / mL bFGF.
- the cells were cultured for 4 days at 37 ° C. and 5% oxygen. At this time, the medium was replaced once every two days with the same conditions.
- the cells were transferred to an incubator with a normal oxygen concentration and cultured for 8 days. At this time, the medium was replaced once every two days.
- Example 2 Screening for cardiomyocyte-specific miRNA candidate substances (1) Selection of cardiomyocytes using MYH6-EIP4 First, an iPS cell line into which an EGFP cassette (MYH6-EIP4) operably linked to the MYH6 promoter was introduced was prepared. The MYH6-EIP4-introduced iPS cell line was prepared by introducing a vector operably linked to an EGFP cassette downstream of MYH (myosin heavy chain) -promoter into 201B7 using the PiggyBac transposon system.
- MYH myosin heavy chain
- the obtained MYH6-EIP4-introduced iPS cell line was treated with 1% L-Glutamine, 150 ⁇ g / mL Transferrin, 50 ⁇ g / mL Ascorbic Acid (sigma), 4 ⁇ 10 ⁇ 4 M monothioglycerol (MTG), 10 uM Rock inhibitor, 0.5% Matrigel and 2 ng / mL BMP4 (R & D) added in STEMPRO 34 (Invitrogen) was cultured at 37 ° C under 5% oxygen condition to form EB (day 0 ). Thereafter, differentiation into cardiomyocytes was induced by the same method as the cardiomyocyte induction method of Example 1. Analysis of cells on day 8 from the start of culture revealed that EGFP-positive cells were observed, suggesting that some cells differentiated into cardiomyocytes at this stage (data not shown).
- the cells on the 8th and 20th days from the start of the culture were collected and divided into EGFP positive cells and EGFP negative cells, respectively, using FACS. Briefly, the collected cell populations (EBs) on days 8 and 20 were treated with collagenase type I for 1 hour and then with trypsin for 5-10 minutes. The cells were dissociated by adding 50% FBS / IMDM to neutralize trypsin and gently pipetting EB. The cells were then centrifuged at 1000 rpm for 5 minutes and resuspended in PBS supplemented with 2% FBS. Cells were sorted using FACS Arial II cell sorter (BD Biosciences) and then analyzed for the expression of Troponin T (TNT).
- EBs collected cell populations
- TNT Troponin T
- miRNA microarray analysis was performed in order to compare miRNA expression profiles between EGFP positive cells and EGFP negative cells sorted on day 8 and day 20, respectively.
- EGFP positive and EGFP negative cells sorted on day 8 and day 20 are lysed using QlAzol lysis reagent (Qiagen) according to the manufacturer's instructions and total RNA is miRNA mini kit.
- Qiagen QlAzol lysis reagent
- Total RNA concentration and purity were determined by measuring the A260 / 280 ratio using a Nanodrop instrument (Thermo Scientific fic).
- RNA amount was confirmed using 2100 Bioanalyzer (Agilent Technologies).
- miRNA expression profiling was performed using Agilent Technologies human miRNA microarray release 19.0 according to the manufacturer's protocol. Data was analyzed using GeneSpring GX 12.6 software program and 46064 technology version was selected.
- Each plasmid DNA used as a template in the preparation of miRNA-responsive off-switch mRNA can be obtained or prepared as described below.
- (A) pTAP-tagBFP Using pTagBFP-Tubulin (evrogen) as a template, fragments were amplified by PCR using TagBFP_Tfwd (5'-GCCACCATGGGATCCAGCGAGCTGATTAAGGAGAAC-3 ') and TagBFP_Trev (5'-ACTCGAGATCTGTGCCCCAGTTTGCTAG-3') as primers. The obtained fragment was inserted into pGEM-TAP, a self-made cloning vector.
- pGEM-TAP was prepared by using pGEM-Teasy (Promega) as a template and pGEMTAP_MCS_Rev (5'-GGGATCCCATGGTGTCGACCTCCTACATATGAGCTCCTGAATTCGCCCTATAGTGATGCG-3 by using pGEMTAP_MCGA TAG (B) pNP-hdKeima-Red Purchased from Institute for Medical Biology (MBL) (# AM-V0274).
- C pCTp-EGFP
- the fragment was amplified by PCR using pEGFP-N1 (Clontech) as a template and YF128_EXFP_Tfwd (5'-GAACCATGGGATCCGTGAGCAAGGGCGAGG-3 ') and YF129_EXFP_Trev (5'-TATGAGATCTCTTGTACAGCTCGTCCATG-3') as primers.
- the obtained fragment was inserted into pCM-TAP, a self-made cloning vector.
- pCM-TAP was prepared by ligating the DraI fragment of pGEM-TAP and the NheI, AgeI blunt-ended fragment of pLysSRARE2 (Novagen).
- pLenti6 / Ubc / V5-DEST Bolastcidin vector
- pLenti6 / Ubc / V5-DEST was purchased from Life Technologies (# V499-10).
- E pPyCAG-Nanog-IP (Puromycin vector)
- pPyCAG-Nanog-IP used Addgene's Plasmid # 13838.
- F pcDNA3.1-HsBimEL It was obtained by the method described in Saito H, et al., Nat Commun. 18; 2: 160 (2011).
- (3-1) Construction of sequences including nucleic acid corresponding to protein coding regions of fluorescent protein-encoding gene, apoptosis-inducing gene and drug-resistance gene Protein-encoding region of fluorescent protein-encoding gene, apoptosis-inducing gene and drug-resistance gene
- the sequence containing the nucleic acid corresponding to was constructed by PCR amplification from each template plasmid using the primers shown in Table 6.
- (A) tagBFP The following solutions were prepared using KOD-Plus-Neo (KOD-401, TOYOBO) according to the manufacturer's instructions.
- the prepared solution was subjected to PCR amplification under the following reaction conditions.
- the amplified PCR product was treated with Dpn I (TOYOBO) at 37 ° C. for 30 minutes and then purified using MiniElute PCR purification Kit (QIAGEN) according to the manufacturer's instructions.
- B EGFP PCR amplification was performed by the same method as in (a) above. TAPEGFP_IVTfwd was used instead of tagBFP fwd as a primer for PCR.
- pCTp-EGFP was used as a template instead of pTAP-tagBFP.
- C hdKeima-Red PCR amplification was performed by the same method as in (a) above.
- hdKeimaRed_IVTfwd and pNP-hdKeima-Red rev were used instead of tagBFP fwd and TAP_IVTrev.
- pNP-hdKeima-Red was used as a template instead of pTAP-tagBFP.
- Bim PCR amplification was performed by the same method as in (a) above.
- Clontech_IVTfwd and BimEL_IVTrev were used instead of tagBFP fwd and TAP_IVTrev.
- pcDNA3.1-HsBimEL human was used as a template instead of pTAP-tagBFP.
- (E) Puromycin PCR amplification was performed by the same method as in (a) above.
- ORF Puromycin Fwd and ORF Puromycin Rev were used instead of tagBFP fwd and TAP_IVTrev.
- pPyCAG-Nanog-IP was used instead of pTAP-tagBFP.
- Blastcidin PCR amplification was performed by the same method as in (a) above.
- ORF Blastcidin Fwd and ORF Blastcidin Rev were used instead of tagBFP fwd and TAP_IVTrev.
- pLenti6 / Ubc / V5-DEST was used instead of pTAP-tagBFP.
- the prepared solution was subjected to PCR amplification under the following reaction conditions.
- the amplified PCR product was purified using MiniElute PCR purification Kit (QIAGEN) according to the manufacturer's instructions.
- D 3'UTR PCR amplification was performed by the same method as in (a) above.
- Fwd3UTR primer and Rev3UTR2T20 were used instead of TAP_T7_G3C fwd primer and Rev5UTR primer.
- IVT_3prime_UTR was used as a template instead of IVT_5prime_UTR.
- IVT template DNA of control mRNA was constructed by PCR amplification using the primers shown in Table 6 and the PCR product amplified as described above.
- IVT_tagBFP The following solutions were prepared using KOD-Plus-Neo (KOD-401, TOYOBO) according to the manufacturer's instructions. The prepared solution was subjected to PCR amplification under the following reaction conditions.
- the amplified PCR product was treated with Dpn I (TOYOBO) at 37 ° C. for 30 minutes and then purified using MiniElute PCR purification Kit (QIAGEN) according to the manufacturer's instructions.
- B IVT_EGFP PCR amplification was performed by the same method as in (a) above. As a template, an EGFP PCR product was used in place of the tagBFP PCR product.
- C IVT Puromycin PCR amplification was performed by the same method as in (a) above. As a template, Puromycin PCR product was used instead of tagBFP PCR product.
- D IVT_ Blastcidin PCR amplification was performed by the same method as in (a) above. As a template, Blastcidin PCR product was used instead of tagBFP PCR product.
- the miRNA-responsive mRNA IVT template was constructed by PCR amplification using the primers in Table 6 and the PCR product amplified above. Further, instead of the 5 ′ UTR PCR product used above, a 5 ′ UTR primer that responds to the miRNA shown in Table 16 below was used.
- IVT_tagBFP The following solutions were prepared using KOD-Plus-Neo (KOD-401, TOYOBO) according to the manufacturer's instructions. The prepared solution was subjected to PCR amplification under the following reaction conditions.
- the amplified PCR product was treated with Dpn I (TOYOBO) at 37 ° C for 30 minutes, and then purified using MiniElute PCR purification Kit (QIAGEN) according to the manufacturer's instructions.
- B IVT_hdKeima-Red PCR amplification was performed by the same method as in (a) above. As a template, the hdKeima-Red PCR product was used instead of the tagBFP PCR product.
- C IVT_Bim PCR amplification was performed by the same method as in (a) above. As a template, a Bim PCR product was used in place of the tagBFP PCR product.
- the reaction mixture was incubated at 37 ° C for 5 hours, TURBO DNase (Amibion) was added, and then incubated at 37 ° C for an additional 30 minutes.
- the obtained mRNA was purified by FavorPrep Blood / Cultured Cells total RNA extraction column (Favorgen Biotech) and incubated at 37 ° C. for 30 minutes using Antarctic phosphatase (New England Biolabs). Then, it further refine
- miRNA-responsive off-switch mRNA (4) Analysis using miRNA-responsive off-switch mRNA.
- they were introduced into cardiomyocytes derived from hiPSC (201B7 strain) together with EGFP mRNA. Briefly, the cell population (EB) on the 16th day after the start of culture was treated with collagenase type I for 1 hour and then with Trypsin for 5-10 minutes. The cells were dissociated by adding 50% FBS / IMDM to neutralize trypsin and gently pipetting EB.
- the cells were then centrifuged at 1000 rpm for 5 minutes and resuspended in StemPro-34 supplemented with 10 ng / ml VEGF and 5 ng / ml bFGF.
- the cells were then seeded at 2 ⁇ 10 5 cells / well in a 24 well plate coated with fibronectin and incubated at 37 ° C., 5% CO 2 for 2 days.
- miRNA-responsive off-switch mRNA was introduced into the cells using a Stemfect RNA transfection kit according to the manufacturer's instructions (Stemgent). Specifically, 12.5 ⁇ l / tube Stemfect Transfection Buffer was placed in two sterilized 1.5 ml tubes.
- 1.0 ⁇ l of Stemfect RNA Transfection Reagent was added to one tube and mixed with the buffer.
- 1.0 ⁇ l of 100 ng / ⁇ l miRNA-responsive off-switch mRNA and 1.0 ⁇ l of 100 ng / ⁇ l EGFP mRNA were added and mixed with the buffer.
- the diluted Transfection Reagent solution was added to the diluted mRNA solution and mixed.
- the mixture was incubated at room temperature for 15 minutes to complete the mRNA complex.
- the culture medium was replaced with 500 ⁇ l of fresh medium (StemPro-34 (without antibiotics) supplemented with 10 ng / ml VEGF and 5 ng / ml bFGF).
- mRNA complex was added to the well and incubated at 37 ° C. under 5% CO 2 for 4 hours. Thereafter, the medium was removed and the cells were washed once with IMDM, and then 500 ⁇ l of fresh medium (StemPro-34 (containing antibiotics) supplemented with 10 ng / ml VEGF and 5 ng / ml bFGF) was added to the wells. After culturing for 2 days, the FFP fluorescence intensity was analyzed by FACS. FACS analysis briefly stated that the collected cell population (EB) was treated with trypsin for 2 minutes and then 50% FBS / IMDM was added to neutralize trypsin. The cells were then centrifuged at 1000 rpm for 5 minutes and resuspended in PBS supplemented with 2% FBS. Thereafter, the cells were subjected to FACS for analysis.
- EB collected cell population
- miR-1-, miR-143-3p-, miR-208a- and miR-499a-5p-responsive off-switch mRNAs were introduced into some cells compared to TagBFP mRNA (control).
- the fluorescence intensity of TagBFP was reduced (FIG. 2).
- cells transfected with miR-490-3p and -490-5p-responsive off-switch mRNA have a reduced fluorescence intensity of TagBFP in most cells compared to TagBFP mRNA (control).
- MiRNA-responsive off-switch mRNA-introduced cells did not respond (FIG. 2). Therefore, miR-1-, miR-143-3p-, miR-208a- and miR-499a-5p-responsive off-switch mRNAs were identified as candidate substances for cardiomyocyte purification.
- Example 3 Purification of cardiomyocytes (1-1) Subsequent experiments were conducted to investigate the effectiveness of miR-1-, miR-143-3p-, miR-208a- and miR-499a-5p-responsive off-switch mRNA in cardiomyocyte purification.
- the 201B7 strain was induced into cardiomyocytes by the cardiomyocyte induction method of Example 1, and on day 20, cells with reduced TagBFP signal were sorted by FACS, and the expression of TNT was analyzed. Briefly, the analysis of TNT expression was performed as follows.
- Sorted cells were fixed with 4% paraformaldehyde in PBS and anti-myocardial TNT isoforms (clone 13-11; Thermo; 1: 200) in PBS containing 2% FBS and 0.5% saponin (Sigma). Stained.
- APC goat anti-mouse Ig (BD pharmingen; 1: 100) was used.
- the introduction of the responsive offswitch mRNA into the cells was performed in the same manner as in Example 2 (4).
- miR-1-, miR-208a- and miR-499a-5p-responsive off-switch mRNA showed high purity for TNT-positive cardiomyocytes, while miR-143-3p
- the miR-490-3p-responsive off-switch mRNA had the same level of purification as when no sorting was performed (FIG. 3).
- the MYH6-EIP6-introduced cell line prepared by the same method as in Example 2 was differentiated into cardiomyocytes by the method of Example 1, and GFP sorting was performed on the 16th day, and 2 days later (18th day).
- miR-1-responsive off-switch mRNA was introduced.
- a cell group into which miR-1-responsive off-switch mRNA was not introduced was also prepared. Total RNA was extracted on the 19th and 25th days and analyzed by microarray.
- Example 4 Purification of cardiomyocytes (1-2)
- 201B7 strain was induced into cardiomyocytes, miRNA-responsive off-switch mRNA was introduced, and it was confirmed whether the cardiomyocytes could be purified with high purity by FACS sorting.
- the induction into cardiomyocytes was carried out by the same method as in Example 1, and the introduction of miRNA-responsive offswitch mRNA into the cells was carried out by the same method as in Example 2 (4).
- miR-1- + miR-208a-, miR-1- + miR-499a-5p- and miR-208a- + miR-499a-5p- The purification efficiency was the same as that of 208a- and miR-499a-5p-alone or slightly better (FIG. 8).
- Example 5 Purification of cardiomyocytes (2) An experiment was conducted to examine the effect of purifying cardiomyocytes when co-introducing miRNA-responsive off-switch mRNA and drug-resistant mRNA into cells.
- the KhES1 strain was induced into cardiomyocytes by the cardiomyocyte induction method of Example 1.
- Introduction of miRNA-responsive off-switch mRNA and drug-resistant mRNA into cells was performed as follows. Briefly, the cell population (EB) on day 16 after the start of culture was treated with collagenase type I for 1 hour and then with 0.25% Trypsin for 5-10 minutes. The cells were dissociated by adding 50% FBS / IMDM to neutralize trypsin and gently pipetting EB.
- the cells were then centrifuged at 1000 rpm for 5 minutes and resuspended in StemPro-34 supplemented with 10 ng / ml VEGF and 5 ng / ml bFGF.
- the cells were then seeded at 5 ⁇ 10 5 cells / well in a 12-well plate coated with fibronectin and incubated for 2 days at 37 ° C., 5% CO 2 .
- miRNA-responsive off-switch mRNA was introduced into the cells using a Stemfect RNA transfection kit according to the manufacturer's instructions (Stemgent). Specifically, 25 ⁇ l / tube Stemfect Transfection Buffer was placed in two sterilized 1.5 ml tubes.
- RNA Transfection Reagent 2 ⁇ l was added to one tube and mixed with the buffer.
- the diluted Transfection Reagent solution was added to the diluted mRNA solution and mixed. The mixture was incubated at room temperature for 15 minutes to complete the mRNA complex.
- the culture medium was replaced with 500 ⁇ l of fresh medium (StemPro-34 (without antibiotics) supplemented with 10 ng / ml VEGF and 5 ng / ml bFGF). After 15 minutes, mRNA complex was added to the well and incubated at 37 ° C. under 5% CO 2 for 4 hours. Thereafter, the medium was removed, the cells were washed once with IMDM, and 500 ⁇ l of fresh medium (StemPro-34 supplemented with 10 ng / ml VEGF and 5 ng / ml bFGF) supplemented with puromycin was added to the wells. After culturing for 2 days, the expression of TNT was analyzed.
- Example 6 Using a neonatal Heart dissociation Kit (Miltenyi Biotech), isolate the heart isolated from a newborn mouse into single cells according to the manufacturer's instructions, and then inoculate a 24-well plate at 2 ⁇ 10 5 cells / well. Incubated at 37 ° C. The next day, Stemfect RNA transfection kit with 100 ng miR-1-, miR-143-3p-, miR-208a-, miR-208b- and miR-499a-5p-responsive offswitch (BFP) with 100 ng EGFP mRNA (Stemgent) and introduced according to the manufacturer's instructions. After 4 hours, after washing the cells, DMEM + 10% FBS was added and cultured for 1 day.
- BFP Stemfect RNA transfection kit with 100 ng miR-1-, miR-143-3p-, miR-208a-, miR-208b- and miR-499a-5p-responsive offswitch
- BFP Stemfect RNA transfection kit with 100
- the obtained cells were treated with 0.25% Trypsin for 2 minutes, and the fluorescence intensity of BFP and EGFP was analyzed by FACS.
- FACS Fluorescence intensity of BFP and EGFP was analyzed by FACS.
- miR-1-BFP, miR-208b-BFP, miR-208a-BFP and miR-499a-5p-BFP can specifically recognize cells contained in the heart including cardiomyocytes.
- the present invention provides a method for selecting and producing cardiomyocytes that can easily purify cardiomyocytes. Therefore, high purity cardiomyocytes for the treatment of heart diseases such as heart failure, ischemic heart disease, myocardial infarction, cardiomyopathy, myocarditis, hypertrophic cardiomyopathy, dilated phase hypertrophic cardiomyopathy, dilated cardiomyopathy Provision is possible.
- heart diseases such as heart failure, ischemic heart disease, myocardial infarction, cardiomyopathy, myocarditis, hypertrophic cardiomyopathy, dilated phase hypertrophic cardiomyopathy, dilated cardiomyopathy Provision is possible.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Developmental Biology & Embryology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
(1)miRNA応答性mRNAを細胞群に導入する工程を含む、心筋細胞の選別方法であって、当該miRNA応答性mRNAが下記:
(i) 心筋細胞で特異的に発現しているmiRNAによって特異的に認識される核酸、および
(ii) 遺伝子のコード領域に対応する核酸
を含む配列からなり、
ここで、当該(ii)の遺伝子のコード領域に対応する核酸のタンパク質への翻訳が当該(i)の核酸配列により制御されている、方法。
(2)前記miRNA応答性mRNAが、miRNA応答性オフスイッチmRNAである、(1)に記載の方法。
(3)前記(i)および(ii)の核酸が、5'から3'の方向にこの順序で連結されている、(1)または(2)に記載の方法。
(4)前記(i)の心筋細胞で特異的に発現しているmiRNAが、miR-1, miR-208a, miR-208bおよびmiR -499a-5pからなる群から選択される1またはそれ以上のmiRNAである、(1)~(3)のいずれかに記載の方法。
(5)前記(ii)の遺伝子が、蛍光タンパク質をコードする遺伝子、アポトーシス誘導遺伝子および自殺遺伝子からなる群から選択される1またはそれ以上の遺伝子である、(1)~(4)のいずれかに記載の方法。
(6)前記蛍光タンパク質をコードする遺伝子が、青色蛍光タンパク質(BFP)をコードする遺伝子である、(5)に記載の方法。
(7)前記アポトーシス誘導遺伝子が、Bimタンパク質をコードする遺伝子である、(5)に記載の方法。
(8)さらに、薬剤耐性遺伝子のコード領域に対応する核酸を含む配列からなるmRNAを細胞群に導入する工程を含む、(1)~(7)のいずれかに記載の方法。
(9)前記薬剤耐性遺伝子が、抗生物質耐性遺伝子である、(8)に記載の方法。
(10)前記抗生物質耐性遺伝子が、ピューロマイシン耐性遺伝子またはブラストサイジン耐性遺伝子である、(9)に記載の方法。
(11)前記工程(a)の細胞群が、多能性幹細胞から分化誘導させた細胞である、(1)~(10)のいずれかに記載の方法。
(12)心筋細胞の製造方法であって、下記:
(a) miRNA応答性mRNAを細胞群に導入する工程、および
(b) 工程(a)のmRNAから翻訳されたタンパク質の量に基づいて当該細胞を選別する工程を
含み、
ここで、当該miRNA応答性mRNAが下記:
(i) 心筋細胞で特異的に発現しているmiRNAによって特異的に認識される核酸、および
(ii) 遺伝子のコード領域に対応する核酸
を含む配列からなり、
上記工程(a)および(b)を行わない場合と比較して、高純度の心筋細胞が得られる、方法。
(13)前記miRNA応答性mRNAが、miRNA応答性オフスイッチmRNAである、(12)に記載の方法。
(14)前記(i)および(ii)の核酸が、5'から3'の方向にこの順序で連結されている、(12)または(13)に記載の方法。
(15)前記(i)の心筋細胞で特異的に発現しているmiRNAが、miR-1, miR-208a, miR-208bおよびmiR-499a-5pからなる群から選択される1またはそれ以上のmiRNAである、(12)~(14)のいずれかに記載の方法。
(16)前記(ii)の遺伝子が、蛍光タンパク質をコードする遺伝子である、(12)~(15)のいずれかに記載の方法。
(17)前記蛍光タンパク質をコードする遺伝子が、BFPをコードする遺伝子である、(16)に記載の方法。
(18)前記工程(a)の細胞群が、多能性幹細胞から分化誘導させた細胞である、(12)~(17)のいずれかに記載の方法。
(19)心筋細胞の製造方法であって、下記:
(a) miRNA応答性mRNAおよび薬剤耐性遺伝子のコード領域に対応する核酸を含む配列からなるmRNAを細胞群に導入する工程、および
(b) 工程(a)の薬剤耐性遺伝子に対応する薬剤の存在下で、工程(a)で得られた細胞を培養する工程を含み、
ここで、当該miRNA応答性mRNAが下記:
(i) 心筋細胞で特異的に発現しているmiRNAによって特異的に認識される核酸、および
(ii) 遺伝子のコード領域に対応する核酸
を含む配列からなり、
上記工程(a)および(b)を行わない場合と比較して、高純度の心筋細胞が得られる、方法。(20)前記miRNA応答性mRNAが、miRNA応答性オフスイッチmRNAである、(19)に記載の方法。
(21)前記(i)および(ii)の核酸が、5'から3'の方向にこの順序で連結されている、(19)または(20)に記載の方法。
(22)前記(i)の心筋細胞で特異的に発現しているmiRNAが、miR-1, miR-208a, miR-208bおよびmiR-499a-5pからなる群から選択される1またはそれ以上のmiRNAである、(19)~(21)のいずれかに記載の方法。
(23)前記(ii)の遺伝子が、アポトーシス誘導遺伝子および/または自殺遺伝子である、(19)~(21)のいずれか1項に記載の方法。
(24)前記アポトーシス誘導遺伝子が、Bimタンパク質をコードする遺伝子である、(23)に記載の方法。
(25)前記薬剤耐性遺伝子が、抗生物質耐性遺伝子である、(19)~(24)のいずれかに記載の方法。
(26)前記抗生物質耐性遺伝子が、ピューロマイシン耐性遺伝子またはブラストサイジン耐性遺伝子である、(25)に記載の方法。
(27)前記工程(a)の細胞群が、多能性幹細胞から分化誘導させた細胞である、(19)~(26)のいずれかに記載の方法。
(28)miRNA応答性mRNAを含む、心筋細胞純化用キットであって、当該miRNA応答性mRNAが下記:
(i) 心筋細胞で特異的に発現しているmiRNAによって特異的に認識される核酸、および
(ii) 遺伝子のコード領域に対応する核酸
を含む配列からなる、キット。
本発明は一つの実施態様によれば、miRNA応答性mRNAを細胞群に導入する工程を含む、心筋細胞を選別する方法を提供する。本実施態様による方法の、導入する工程において、miRNA応答性mRNAが導入され、選別の対象となる細胞群は、心筋細胞を含有しうる任意の細胞であって良い。例えば、多能性幹細胞から分化誘導させた細胞群であってもよく、生体内から取り出した細胞の集団であってもよいが、これらには限定されない。したがって、心筋細胞を含有するか否かが不明な細胞群にmiRNA応答性mRNAを導入することもあり得る。好ましい実施態様において、細胞群は、多能性幹細胞から分化誘導された細胞群であり得る。多能性幹細胞から分化誘導された細胞群とは、後に詳述する方法により、多能性幹細胞から心筋細胞へと分化誘導させる工程を経た細胞群であって、分化誘導されて心筋細胞となった細胞と、心筋細胞にまで分化されなかった細胞とを含有しうる。多能性幹細胞は、特に限定されることはないが、例えば、下記のものが挙げられる。
胚性幹細胞(ES細胞)は、ヒトやマウスなどの哺乳動物の初期胚(例えば胚盤胞)の内部細胞塊から樹立された、多能性と自己複製による増殖能を有する幹細胞である。
al. (1996), Biol. Reprod., 55:254-259; J.A. Thomson and V.S. Marshall (1998), Curr. Top. Dev. Biol., 38:133-165)。
精子幹細胞は、精巣由来の多能性幹細胞であり、精子形成のための起源となる細胞である。この細胞は、ES細胞と同様に、種々の系列の細胞に分化誘導可能であり、例えばマウス胚盤胞に移植するとキメラマウスを作出できるなどの性質をもつ(M. Kanatsu-Shinohara et al. (2003) Biol. Reprod., 69:612-616; K. Shinohara et al. (2004), Cell, 119:1001-1012)。神経膠細胞系由来神経栄養因子(glial cell line-derived neurotrophic factor (GDNF))を含む培養液で自己複製可能であるし、またES細胞と同様の培養条件下で継代を繰り返すことによって、精子幹細胞を得ることができる(竹林正則ら(2008),実験医学,26巻,5号(増刊),41~46頁,羊土社(東京、日本))。
胚性生殖細胞は、胎生期の始原生殖細胞から樹立される、ES細胞と同様な多能性をもつ細胞であり、LIF、bFGF、幹細胞因子(stem cell factor)などの物質の存在下で始原生殖細胞を培養することによって樹立しうる(Y. Matsui et al. (1992), Cell, 70:841-847; J.L. Resnick et al. (1992), Nature, 359:550-551)。
人工多能性幹(iPS)細胞は、特定の初期化因子を、DNA、RNA又はタンパク質の形態で体細胞に導入することによって作製することができる、ES細胞とほぼ同等の特性、例えば分化多能性と自己複製による増殖能、を有する体細胞由来の人工の幹細胞である(K. Takahashi and S. Yamanaka (2006) Cell, 126:663-676; K. Takahashi et al. (2007), Cell, 131:861-872; J. Yu et al. (2007), Science, 318:1917-1920; Nakagawa, M.ら,Nat. Biotechnol. 26:101-106 (2008);国際公開WO 2007/069666)。初期化因子は、ES細胞に特異的に発現している遺伝子、その遺伝子産物もしくはnon-cording RNAまたはES細胞の未分化維持に重要な役割を果たす遺伝子、その遺伝子産物もしくはnon-coding RNA、あるいは低分子化合物によって構成されてもよい。初期化因子に含まれる遺伝子として、例えば、Oct3/4、Sox2、Sox1、Sox3、Sox15、Sox17、Klf4、Klf2、c-Myc、N-Myc、L-Myc、Nanog、Lin28、Fbx15、ERas、ECAT15-2、Tcl1、beta-catenin、Lin28b、Sall1、Sall4、Esrrb、Nr5a2、Tbx3またはGlis1等が例示され、これらの初期化因子は、単独で用いても良く、組み合わせて用いても良い。初期化因子の組み合わせとしては、WO2007/069666、WO2008/118820、WO2009/007852、WO2009/032194、WO2009/058413、WO2009/057831、WO2009/075119、WO2009/079007、WO2009/091659、WO2009/101084、WO2009/101407、WO2009/102983、WO2009/114949、WO2009/117439、WO2009/126250、WO2009/126251、WO2009/126655、WO2009/157593、WO2010/009015、WO2010/033906、WO2010/033920、WO2010/042800、WO2010/050626、WO 2010/056831、WO2010/068955、WO2010/098419、WO2010/102267、WO 2010/111409、WO 2010/111422、WO2010/115050、WO2010/124290、WO2010/147395、WO2010/147612、Huangfu D, et al. (2008), Nat. Biotechnol., 26: 795-797、Shi Y, et al. (2008), Cell Stem Cell, 2: 525-528、Eminli S, et al. (2008), Stem Cells. 26:2467-2474、Huangfu D, et al. (2008), Nat Biotechnol. 26:1269-1275、Shi Y, et al. (2008), Cell Stem Cell, 3, 568-574、Zhao Y, et al. (2008), Cell Stem Cell, 3:475-479、Marson A, (2008), Cell Stem Cell, 3, 132-135、Feng B, et al. (2009), Nat Cell Biol. 11:197-203、R.L. Judson et al., (2009), Nat. Biotech., 27:459-461、Lyssiotis CA, et al. (2009), Proc Natl Acad Sci U S A. 106:8912-8917、Kim JB, et al. (2009), Nature. 461:649-643、Ichida JK, et al. (2009), Cell Stem Cell. 5:491-503、Heng JC, et al. (2010), Cell Stem Cell. 6:167-74、Han J, et al. (2010), Nature. 463:1096-100、Mali P, et al. (2010), Stem Cells. 28:713-720、Maekawa M, et al. (2011), Nature. 474:225-9.に記載の組み合わせが例示される。
(例えば、5-azacytidine)、ヒストンメチルトランスフェラーゼ阻害剤(例えば、BIX-01294 等の低分子阻害剤、Suv39hl、Suv39h2、SetDBlおよびG9aに対するsiRNAおよびshRNA等の核酸性発現阻害剤など)、L-channel calcium agonist (例えばBayk8644)、酪酸、TGFβ阻害剤またはALK5阻害剤(例えば、LY364947、SB431542、616453およびA-83-01)、p53阻害剤(例えばp53に対するsiRNAおよびshRNA)、ARID3A阻害剤(例えば、ARID3Aに対するsiRNAおよびshRNA)、miR-291-3p、miR-294、miR-295およびmir-302などのmiRNA、Wnt Signaling(例えばsoluble Wnt3a)、神経ペプチドY、プロスタグランジン類(例えば、プロスタグランジンE2およびプロスタグランジンJ2)、hTERT、SV40LT、UTF1、IRX6、GLISl、PITX2、DMRTBl等の樹立効率を高めることを目的として用いられる因子も含まれており、本明細書においては、これらの樹立効率の改善目的にて用いられた因子についても初期化因子と別段の区別をしないものとする。
核移植により得られたクローン胚由来のES細胞(nt ES細胞)は、核移植技術によって作製されたクローン胚由来のES細胞であり、受精卵由来のES細胞とほぼ同じ特性を有している(T. Wakayama et al. (2001), Science, 292:740-743; S. Wakayama et al. (2005), Biol. Reprod., 72:932-936; J. Byrne et al. (2007), Nature, 450:497-502)。すなわち、未受精卵の核を体細胞の核と置換することによって得られたクローン胚由来の胚盤胞の内部細胞塊から樹立されたES細胞がnt ES(nuclear transfer ES)細胞である。nt ES細胞の作製のためには、核移植技術(J.B. Cibelli et al. (1998), Nature Biotechnol., 16:642-646)とES細胞作製技術との組み合わせが利用される(若山清香ら(2008),実験医学,26巻,5号(増刊), 47~52頁)。核移植においては、哺乳動物の除核した未受精卵に、体細胞の核を注入し、数時間培養することで初期化することができる。
Multilineage-differentiating Stress Enduring cells (Muse細胞)は、WO2011/007900に記載された方法にて製造された多能性幹細胞であり、詳細には、線維芽細胞または骨髄間質細胞を長時間トリプシン処理、好ましくは8時間または16時間トリプシン処理した後、浮遊培養することで得られる多能性を有した細胞であり、SSEA-3およびCD105が陽性である。
本発明において「心筋細胞」とは、少なくとも心筋トロポニン(cTnT)またはαMHCを発現している細胞を意味する。cTnTは、ヒトの場合NCBIのaccession番号NM_000364が例示され、マウスの場合、NM_001130174が例示される。αMHCは、ヒトの場合NCBIのaccession番号NM_002471が例示され、マウスの場合、NM_001164171が例示される。本発明における心筋細胞の由来は特に問われず、例えば、任意の方法で得られた末梢血、心臓、骨髄組織、脂肪組織、骨格筋組織、羊膜組織、胎盤組織、臍帯血などに含まれる細胞であってもよいし、また、多能性幹細胞から分化誘導された細胞であってもよい。
本発明において、多能性幹細胞を解離させる工程においては、互いに接着して集団を形成している細胞を個々の細胞に解離(分離)させる。多能性幹細胞を解離させる方法としては、例えば、力学的に解離する方法、プロテアーゼ活性とコラゲナーゼ活性を有する解離溶液(例えば、Accutase(TM)およびAccumax(TM)など)またはコラゲナーゼ活性のみを有する解離溶液を用いた解離方法が挙げられる。好ましくは、プロテアーゼ活性とコラゲナーゼ活性を有する解離溶液(特に好ましくは、Accumax)を用いて多能性幹細胞を解離する方法が用いられる。
本工程において用いる培養液は、動物細胞の培養に用いられる培地を基礎培地へアクチビンA、BMP4およびbFGFを添加することにより調製することができる。基礎培地としては、例えばIMDM培地、Medium 199培地、Eagle's Minimum Essential Medium (EMEM)培地、αMEM培地、Dulbecco's modified Eagle's Medium (DMEM)培地、Ham's F12培地、RPMI 1640培地、Fischer's培地、Neurobasal Medium(ライフテクノロジーズ)、StemPro34(invitrogen)およびこれらの混合培地などが包含される。培地には、血清が含有されていてもよいし、あるいは無血清でもよい。必要に応じて、培地は、例えば、アルブミン、トランスフェリン、Knockout Serum Replacement(KSR)(ES細胞培養時のFBSの血清代替物)、N2サプリメント(Invitrogen)、B27サプリメント(Invitrogen)、脂肪酸、インスリン、コラーゲン前駆体、微量元素、2-メルカプトエタノール、1-チオールグリセロールなどの1つ以上の血清代替物を含んでもよいし、脂質、アミノ酸、L-グルタミン、Glutamax(Invitrogen)、非必須アミノ酸、ビタミン、増殖因子、低分子化合物、抗生物質、抗酸化剤、ピルビン酸、緩衝剤、無機塩類などの1つ以上の物質も含有し得る。好ましい基礎培地は、トランスフェリン、1-チオールグリセロール、L-グルタミン、アスコルビン酸を含有するStemPro34である。
本工程において用いる培養液は、動物細胞の培養に用いられる培地を基礎培地へVEGFおよびWnt阻害剤を添加することにより調製することができる。基礎培地としては、例えばIMDM培地、Medium 199培地、Eagle's Minimum Essential Medium (EMEM)培地、αMEM培地、Dulbecco's modified Eagle's Medium (DMEM)培地、Ham's F12培地、RPMI 1640培地、Fischer's培地、Neurobasal Medium(ライフテクノロジーズ)、StemPro34(invitrogen)およびこれらの混合培地などが包含される。培地には、血清が含有されていてもよいし、あるいは無血清でもよい。必要に応じて、培地は、例えば、アルブミン、トランスフェリン、Knockout Serum Replacement(KSR)(ES細胞培養時のFBSの血清代替物)、N2サプリメント(Invitrogen)、B27サプリメント(Invitrogen)、脂肪酸、インスリン、コラーゲン前駆体、微量元素、2-メルカプトエタノール、1-チオールグリセロールなどの1つ以上の血清代替物を含んでもよいし、脂質、アミノ酸、L-グルタミン、Glutamax(Invitrogen)、非必須アミノ酸、ビタミン、増殖因子、低分子化合物、抗生物質、抗酸化剤、ピルビン酸、緩衝剤、無機塩類などの1つ以上の物質も含有し得る。好ましい基礎培地は、トランスフェリン、1-チオールグリセロール、L-グルタミン、アスコルビン酸を含有するStemPro34である。
本工程において用いる培養液は、動物細胞の培養に用いられる培地を基礎培地へVEGFおよびbFGFを添加することにより調製することができる。基礎培地としては、例えばIMDM培地、Medium 199培地、Eagle's Minimum Essential Medium (EMEM)培地、αMEM培地、Dulbecco's modified Eagle's Medium (DMEM)培地、Ham's F12培地、RPMI 1640培地、Fischer's培地、Neurobasal Medium(ライフテクノロジーズ)、StemPro34(invitrogen)およびこれらの混合培地などが包含される。培地には、血清が含有されていてもよいし、あるいは無血清でもよい。必要に応じて、培地は、例えば、アルブミン、トランスフェリン、Knockout Serum Replacement(KSR)(ES細胞培養時のFBSの血清代替物)、N2サプリメント(Invitrogen)、B27サプリメント(Invitrogen)、脂肪酸、インスリン、コラーゲン前駆体、微量元素、2-メルカプトエタノール、1-チオールグリセロールなどの1つ以上の血清代替物を含んでもよいし、脂質、アミノ酸、L-グルタミン、Glutamax(Invitrogen)、非必須アミノ酸、ビタミン、増殖因子、低分子化合物、抗生物質、抗酸化剤、ピルビン酸、緩衝剤、無機塩類などの1つ以上の物質も含有し得る。好ましい基礎培地は、トランスフェ
リン、1-チオールグリセロール、L-グルタミン、アスコルビン酸を含有するStemPro34である。
することができる。例えば、cap構造と標的配列内のAUG配列との間の塩基数が、0~60塩基、例えば、0~15塩基、10~20塩基、20~30塩基、30~40塩基、40~50塩基、50~60塩基となるような配置にて設計され得る。
また、薬剤耐性遺伝子のコード領域に対応する核酸を含む配列からなるコントロールmRNAは、任意のマーカー遺伝子のコード領域に対応する核酸を含む配列からなるmiRNA応答性mRNAとともに用いることができる。この場合、マーカー遺伝子の種類に関わらず、miRNA応答性mRNAが導入された細胞が選択的に薬剤耐性を有することになり、選別の精度向上を図ることができる。
一方、miRNA応答性mRNAに含まれるマーカー遺伝子およびコントロールmRNAに含まれるマーカー遺伝子は、その両者に同種の遺伝子が用いられることもあり得る。例えば、miRNA応答性mRNAに含まれるマーカー遺伝子とコントロールmRNAに含まれるマーカー遺伝子の両者に蛍光タンパク質をコードする遺伝子が用いられることがあり得て、この場合には、両蛍光タンパク質の蛍光波長が異なることが望ましい。
なお、蛍光タンパク質をコードする遺伝子に替えて、発光タンパク質あるいは、蛍光、発光又は呈色を補助するタンパク質をコードする遺伝子を同様の組み合わせで用いることも可能である。
本発明の一つの態様として、FACSによる選別を用いた方法を提供する。すなわち、本発明は、心筋細胞の製造方法であって、下記:
(a) miRNA応答性mRNAを細胞群に導入する工程、および
(b) 工程(a)のmiRNA応答性mRNAから翻訳されたタンパク質の量に基づいて当該心筋細胞を選別する工程を含み、
ここで、当該miRNA応答性mRNAが下記:
(i) 心筋細胞で特異的に発現しているmiRNAによって特異的に認識される核酸、および
(ii) 遺伝子のコード領域に対応する核酸
を含む配列からなり、
上記工程(a)および(b)を行わない場合と比較して、高純度の心筋細胞を回収できる、方法を提供する。なお、当該miRNA応答性mRNAに含有される(ii)の遺伝子の翻訳量がより少ない細胞を選択することによって心筋細胞を回収できる。
本発明の別の態様として、FACSによる選別を必要としない方法を提供する。すなわち、本発明は、心筋細胞の製造方法であって、下記:
(a) miRNA応答性mRNAおよび薬剤耐性遺伝子のコード領域に対応する核酸を含む配列から
なるmRNAを細胞群に導入する工程、および
(b) 工程(a)の薬剤耐性遺伝子に対応する薬剤の存在下で、工程(a)で得られた細胞群を培養する工程を含み、
ここで、当該miRNA応答性mRNAが下記:
(i) 心筋細胞で特異的に発現しているmiRNAによって特異的に認識される核酸、および
(ii) 遺伝子のコード領域に対応する核酸
を含む配列からなり、
上記工程(a)および(b)を行わない場合と比較して、高純度の心筋細胞を回収できる、方法を提供する。
本発明の別の態様として、心筋細胞を高純度で選別し、あるいは製造するためのキットを提供する。本発明における心筋細胞純化用キットは、miRNA応答性mRNAを含むキットであり得る。本発明のキットに包含されるmiRNA応答性mRNAは特に限定されないが、好ましくは、miRNA応答性オフスイッチmRNAが用いられる。具体的なmiRNA応答性mRNAの構成については、上記心筋細胞の選別方法、心筋細胞の製造方法に記載したとおりである。本発明のキットは、これらの方法において説明したmiRNA応答性mRNA、ならびに複数のmiRNA応答性mRNAの全ての組み合わせを含み得る。
本発明で得られた心筋細胞は、選別工程で得られた心筋細胞をそのままで、あるいは、任意選択的に、通常行われている方法で、選別工程で得られた心筋細胞を含む細胞群から死細胞や混入物を除去する工程を経て、動物(好ましくはヒト)の心疾患の治療剤として用いることができる。心疾患の治療方法として、例えば、得られた心筋細胞を生理食塩水等に懸濁させ、直接心臓の心筋層へ投与してもよく、あるいは得られた心筋細胞をシート化して、患者の心臓に貼付することによって行われてもよい。前者の場合、細胞単体で投与してもよく、好ましくは、生着を促すような足場材と共に投与され得る。ここで足場材とは、コラーゲンなどの生体由来の成分やこれに代替するポリ乳酸などの合成ポリマーが例示されるが、これらに限定されない。心筋シートを投与する場合、所望の部分を覆うように配置することによって達成される。ここで、所望の部分を覆うように配置することは、当該分野において周知技術を用いて行うことができる。配置に際し、所望の部分が大きい場合は、組織を取り巻くように配置してもよい。また、投与は、所望の効果を得るため、同部分へ数回の配置を行うこともできる。数回の配置を行う場合、所望の細胞が組織へ生着し、血管新生を行うために十分な時間をおいて行うことが望ましい。このような心疾患の治療の機序は、心筋シートの生着により生じる効果であってもよく、あるいは細胞の生着によらない間接的な作用(例えば、誘引物質を分泌することによるレシピエント由来細胞の損傷部位への動員による効果)であってもよい。心疾患の治療において、心筋シートを用いる場合には、心筋細胞に加えて、コラーゲン、フィブロネクチン、ラミニン等の細胞足場材料(スキャホールド)を含んでいてもよい。あるいは、心筋細胞の他に、任意の細胞種(複数も可)を含んでいることも可能である。本発明において治療され得る心疾患は、心不全、虚血性心疾患、心筋梗塞、心筋症、心筋炎、肥大型心筋症、拡張相肥大型心筋症、拡張型心筋症などの疾患または障害による欠損等が挙げられるがこれらに限定されない。
多能性幹細胞
201B7株(Takahashi K, et al. Cell. 131: 861-72, 2007)、409B2株、947A2株およびKhES1株として以下の株を用いた。
(1)201B7株は、Takahashi K, et al. Cell. 131: 861-72, 2007に記載の方法で作製された。
(2)409B2株
Okita. K, et al., Stem Cells. 2012 Nov 29.に記載の方法に基づき、ヒト皮膚細胞にエピソーマルベクター(pCXLE-hOCT3/4-shp53-F、pCXLE-hSK、pCXLE-hUL)を電気穿孔法で遺伝子導入し、マイトマイシン処理したマウス胎仔線維芽細胞フィーダー上で培養することにより、iPS細胞株を作製した。培養は、従来の方法で行った(Takahashi K, et al. Cell. 131: 861-72, 2007およびNakagawa M, et al. Nat Biotechnol. 26: 101-6, 2008)。(3)947A2株
上記409B2株と同様の方法を用いて、ヒト末梢血細胞からiPS細胞株を作製した。培養についても、上記409B2株と同様の方法で行った。
(4)KhES1株
ヒトES細胞は、京都大学再生医科学研究所附属幹細胞医学研究センターによって樹立されたKhES1株を用い、従来の方法で培養した(Suemori H, et al. Biochem Biophys Res Commun. 345:926-32, 2006)。
201B7細胞株、409B2株、947A2株またはKhES1株をCTK solution(ReproCELL)で2分処理後、溶液を除去し、続いてAccumax(Innovative Cell Technologies)で5分処理後、ピペッティングによりシングルセルへと解離した。遠心分離により細胞を回収し、低接着6 wellディッシュ(Corning)へ移し、2mM L-Glutamine、150μg/mL Transferrin、50μg/mL Ascorbic Acid(sigma)、4×10-4M monothioglycerol (MTG)および2ng/mL BMP4(R&D)を添加した1.5 ml/well STEMPRO 34(Invitrogen)中、37℃、5%酸素条件下にて培養して、EBを形成させた(day0)。
心筋細胞特異的miRNA候補物質のスクリーニング
(1)MYH6-EIP4による心筋細胞の選別
最初に、MYH6プロモーターに作動可能に結合したEGFPのカセット(MYH6-EIP4)を導入したiPS細胞株を作製した。MYH6-EIP4導入iPS細胞株の作製は、PiggyBacトランスポゾンシステムを用いて、MYH(myosin heavy chain)-promoterの下流にEGFPカセットを作動可能に連結したベクターを201B7に導入することにより行われた。心筋細胞への分化を誘導するために、得られたMYH6-EIP4導入iPS細胞株を、1% L-Glutamine、150μg/mL Transferrin、50μg/mL Ascorbic Acid(sigma)、4×10-4M monothioglycerol (MTG)、10uM Rock inhibitor、0.5% Matrigelおよび2ng/mL BMP4(R&D)を添加したSTEMPRO 34(Invitrogen)中、37℃、5%酸素条件下にて培養して、EBを形成させた(day0)。その後、実施例1の心筋細胞誘導法と同様の方法で、心筋細胞への分化誘導を行った。培養開始から8日目の細胞を解析したところ、EGFP陽性細胞が観察されたことから、この段階で心筋細胞へ分化している細胞が存在することが示唆された(データは示していない)。
続いて、8日目と20日目のそれぞれでソーティングされたEGFP陽性細胞とEGFP陰性細胞間のmiRNAの発現プロファイルを比較するために、miRNAマイクロアレイ解析を行った。簡潔には、8日目と20日目のそれぞれでソーティングされたEGFP陽性細胞とEGFP陰性細胞を、製造者の指示に従って、QlAzol lysis reagent (Qiagen)を用いて溶解し、miRNA Mini Kitにより全RNAを精製した。Nanodrop instrument (Thermo Scienticfic)を用いてA260/280比率を測定することにより、全RNA濃度および純度を決定した。マイクロアレイのために、2100 Bioanalyzer (Agilent Technologies)を用いてRNA量の確認を行った。続いて、Agilent Technologies human miRNA microarray release 19.0を用いて、製造者のプロトコールに従い、miRNA発現プロファイリングを行った。GeneSpring GX 12.6 software programを用いてデータを解析し、46064 technology versionを選択した。
miRNA応答性オフスイッチmRNAの各構成要素を構築するためのプライマー配列について、一覧を下記の表に示す。fwdはフォワードプライマーであり、revはリバースプライマーを示す。
(a)pTAP-tagBFP
pTagBFP-Tubulin (evrogen) を鋳型にして、プライマーとして、TagBFP_Tfwd (5’-GCCACCATGGGATCCAGCGAGCTGATTAAGGAGAAC-3’) およびTagBFP_Trev (5’-ACTCGAGATCTGTGCCCCAGTTTGCTAG-3’) を用いて、PCR 法により断片を増幅した。得られた断片を、自作のクローニングベクターであるpGEM-TAP に挿入した。pGEM-TAPは、pGEM-Teasy (Promega) を鋳型にして、プライマーとして、pGEMTAP_MCS_Rev (5’-GGGATCCCATGGTGTCGACCTGCAGCATATGAGCTCCTGAATTCGCCCTATAGTGAGTCG-3’) およびpGEMTAP_MCS_Fwd (5’-GGGAGATCTCATATGCATCTCGAGTGATAGTCTAGACAAGCTTGAGTATTCTATAGTGTCACC-3’) を用いて、PCR mutagenesisにより作製した。
(b)pNP-hdKeima-Red
株式会社医学生物学研究所(MBL)より購入した(#AM-V0274)。
(c)pCTp-EGFP
pEGFP-N1 (Clontech) を鋳型にして、プライマーとして、YF128_EXFP_Tfwd (5’-GAACCATGGGATCCGTGAGCAAGGGCGAGG-3’)およびYF129_EXFP_Trev (5’-TATGAGATCTCTTGTACAGCTCGTCCATG-3’)を用いて、PCR 法により断片を増幅した。得られた断片を、自作のクローニングベクターであるpCM-TAPに挿入した。pCM-TAPは、上記pGEM-TAPのDraI 断片と pLysSRARE2 (Novagen) のNheI, AgeI 平滑末端化断片をライゲーションすることにより作製した。
(d)pLenti6/Ubc/V5-DEST(Blastcidin vector)
pLenti6/Ubc/V5-DESTは、Life Technologies社より購入した(#V499-10)。
(e)pPyCAG-Nanog-IP(Puromycin vector)
pPyCAG-Nanog-IPは、AddgeneのPlasmid #13838を使用した。
(f)pcDNA3.1-HsBimEL
Saito H, et al., Nat Commun. 18;2:160 (2011)に記載の方法により入手した。
蛍光タンパク質をコードする遺伝子、アポトーシス誘導遺伝子および薬剤耐性遺伝子のタンパク質コード領域に対応する核酸を含む配列の構築は、それぞれの鋳型プラスミドから表6のプライマーを用いてPCR増幅を行った。
(a)tagBFP
KOD-Plus-Neo(KOD-401,TOYOBO)を用いて、製造者の指示に従って、下記の溶液を調整した。
(b)EGFP
上記(a)と同様の方法により、PCR増幅を行った。PCR用のプライマーとして、tagBFP fwdの代わりに、TAPEGFP_IVTfwdを用いた。また、鋳型として、pTAP-tagBFPの代わりにpCTp-EGFPを用いた。
(c)hdKeima-Red
上記(a)と同様の方法により、PCR増幅を行った。PCR用のプライマーとして、tagBFP fwdおよびTAP_IVTrevの代わりに、hdKeimaRed_IVTfwdおよびpNP-hdKeima-Red revを用いた。また、鋳型として、pTAP-tagBFPの代わりにpNP-hdKeima-Redを用いた。
(d)Bim
上記(a)と同様の方法により、PCR増幅を行った。PCR用のプライマーとして、tagBFP fwdおよびTAP_IVTrevの代わりに、Clontech_IVTfwdおよびBimEL_IVTrevを用いた。また、鋳型として、pTAP-tagBFPの代わりにpcDNA3.1-HsBimEL humanを用いた。
(e)Puromycin
上記(a)と同様の方法により、PCR増幅を行った。PCR用のプライマーとして、tagBFP fwdおよびTAP_IVTrevの代わりに、ORF Puromycin FwdおよびORF Puromycin Revを用いた。また、鋳型として、pTAP-tagBFPの代わりにpPyCAG-Nanog-IPを用いた。
(f)Blastcidin
上記(a)と同様の方法により、PCR増幅を行った。PCR用のプライマーとして、tagBFP fwdおよびTAP_IVTrevの代わりに、ORF Blastcidin FwdおよびORF Blastcidin Revを用いた。また、鋳型として、pTAP-tagBFPの代わりにpLenti6/Ubc/V5-DESTを用いた。
5’UTRおよび3’UTR配列の構築は、それぞれの鋳型から表6のプライマーを用いてPCR増幅を行った。
(a)5’UTR
KOD-Plus-Neo(KOD-401,TOYOBO)を用いて、製造者の指示に従って、下記の溶液を調整した。
(d)3’UTR
上記(a)と同様の方法により、PCR増幅を行った。PCR用のプライマーとして、TAP_T7_G3C fwd primerおよびRev5UTR primerの代わりに、Fwd3UTR primerおよびRev3UTR2T20を用いた。また、鋳型として、IVT_5prime_UTRの代わりにIVT_3prime_UTRを用いた。
コントロールmRNAのIVTテンプレートの構築は、表6のプライマー及び上記で増幅されたPCR産物を用いてPCR増幅を行った。
(a)IVT_tagBFP
KOD-Plus-Neo(KOD-401,TOYOBO)を用いて、製造者の指示に従って、下記の溶液を調整した。
(b)IVT_EGFP
上記(a)と同様の方法により、PCR増幅を行った。鋳型として、tagBFP PCR産物の代わりにEGFP PCR産物を用いた。
(c)IVT Puromycin
上記(a)と同様の方法により、PCR増幅を行った。鋳型として、tagBFP PCR産物の代わりにPuromycin PCR産物を用いた。
(d)IVT_ Blastcidin
上記(a)と同様の方法により、PCR増幅を行った。鋳型として、tagBFP PCR産物の代わりにBlastcidin PCR産物を用いた。
miRNA応答性mRNAのIVTテンプレートの構築は、表6のプライマー及び上記で増幅されたPCR産物を用いてPCR増幅を行った。また、上記で用いた5’UTR PCR産物の代わりに、下記の表16で示したmiRNAに応答する5’UTRプライマーを用いた。
(b)IVT_hdKeima-Red
上記(a)と同様の方法により、PCR増幅を行った。鋳型として、tagBFP PCR産物の代わりにhdKeima-Red PCR産物を用いた。
(c)IVT_Bim
上記(a)と同様の方法により、PCR増幅を行った。鋳型として、tagBFP PCR産物の代わりにBim PCR産物を用いた。
Warren L, et al., Cell Stem Cell. 7(5):618-30 (2010) に記載のプロトコールを用いて、MEGAscript T7 kit (Ambion)により、miRNA応答性オフスイッチmRNAを作製した。この反応において、ウリジン三リン酸及びシチジン三リン酸に替えて、シュードウリジン-5’ -三リン酸及びメチルシチジン-5’-三リン酸(TriLink BioTechnologies)をそれぞれ用いた。IVT(mRNA合成)反応の前に、グアニジン-5’-三リン酸は、Anti Reverse cap Analog (New England Biolabs)で5倍希釈した。反応混合液を37°Cで5時間インキュベートして、TURBO DNase (Amibion)を加えた後、37°Cでさらに30分インキュベートした。得られたmRNAは、FavorPrep Blood / Cultured Cells total RNA extraction column (Favorgen Biotech)で精製し、Antarctic phosphatase (New England Biolabs)を用いて37C°で30分インキュベートした。その後、RNeasy Mini Elute Cleanup Kit (QIAGEN)により、さらに精製した。
作製したmiRNA応答性オフスイッチmRNAを評価するために、それらをEGFP mRNAと共にhiPSC(201B7株)由来の心筋細胞に導入した。簡潔には、培養開始後16日目の細胞集団(EB)をcollagenase type Iで1時間、次いでTrypsinで5-10分間処理した。そこに50%FBS/IMDMを加えてトリプシンを中和し、EBを穏やかにピペッティングして、細胞を解離した。その後、細胞を1000 rpmで5分間遠心分離し、10ng/ml VEGFおよび5 ng/ml bFGFを添加したStemPro-34に再懸濁した。その後、細胞をフィブロネクチンでコートした24ウェルプレートに2×105細胞/ウェルで播種し、37℃、5%CO2下で2日間インキュベートした。次いで、Stemfect RNA transfection kitを用いて、製造者(Stemgent)の指示に従って、miRNA応答性オフスイッチmRNAを細胞に導入した。具体的には、12.5μl / tube Stemfect Transfection Buffer を2つの滅菌した1.5ml tubeへ入れた。次いで、一方のtubeに、1.0μlのStemfect RNA Transfection Reagentを加えてバッファーと混合した。もう一方のtubeには、100 ng/ μl miRNA応答性オフスイッチmRNAを1.0 μlと100 ng/ μl EGFP mRNAを1.0 μl加えて、バッファーと混合した。希釈したTransfection Reagent溶液を希釈したmRNA溶液に加えて混合した。混合物を室温で15分間インキュベートして、mRNA complexを完成させた。その間に、培養培地を500μlのfreshな培地(10ng/ml VEGFおよび5 ng/ml bFGFを添加したStemPro-34(抗生物質不含))に交換しておき、15分経った時点で、mRNA complexをwellに加えて、37℃、5%CO2下で4時間インキュベートした。その後、培地を除き、細胞をIMDMで一度洗浄してから、500μlのfreshな培地(10ng/ml VEGFおよび5 ng/ml bFGFを添加したStemPro-34(抗生物質含))をウェルに加えた。2日間培養し、その後、BFPの蛍光強度についてFACSによる解析を行った。FACS解析は、簡潔には、回収した細胞集団(EB)をトリプシンで2分間処理し、次いで、50%FBS/IMDMを加えてトリプシンを中和した。その後、細胞を1000 rpmで5分間遠心分離し、2%FBSを添加したPBSに再懸濁した。その後、細胞をFACSにかけて解析を行った。
心筋細胞の純化(1-1)
心筋細胞の純化におけるmiR-1-, miR-143-3p-, miR-208a-およびmiR-499a-5p-応答性オフスイッチmRNAの有効性について調べるために、引き続き実験を行った。実施例1の心筋細胞誘導法により201B7株を心筋細胞へ誘導し、20日目に、TagBFPシグナルが減少した細胞をFACSによりソーティングし、TNTの発現について解析を行った。TNT発現の解析は、簡潔には、下記の通り行った。ソーティングした細胞群を、PBS中、4% paraformaldehydeで固定し、2% FBSおよび0.5% saponin (Sigma)を含有するPBS中、抗心筋TNTアイソフォーム(clone 13-11; Thermo; 1:200)で染色した。二次抗体としては、APC goat anti-mouse Ig(BD pharmingen; 1:100)を用いた。応答性オフスイッチmRNAの細胞への導入については、実施例2(4)と同様の方法で行った。
心筋細胞の純化(1-2)
複数のmiRNA応答性オフスイッチmRNAを組み合わせた場合の心筋細胞の純化における有効性について調べるために、下記の実験を行った。すなわち、201B7株を心筋細胞へ誘導して、miRNA応答性オフスイッチmRNAを導入し、FACSでのソーティングにより心筋細胞を高純度で精製できるかを確かめた。心筋細胞への誘導については、実施例1と同様の方法により、miRNA応答性オフスイッチmRNA の細胞への導入については、実施例2(4)と同様の方法により行った。
心筋細胞の純化(2)
miRNA応答性オフスイッチmRNAと薬剤耐性mRNAを細胞に共導入した際の心筋細胞純化効果を調べるために、実験を行った。実施例1の心筋細胞誘導法によりKhES1株を心筋細胞へ誘導した。miRNA応答性オフスイッチmRNAと薬剤耐性mRNAの細胞への導入については、下記の通り行った。簡潔には、培養開始後16日目の細胞集団(EB)をcollagenase type Iで1時間、次いで0.25%Trypsinで5-10分間処理した。そこに50%FBS/IMDMを加えてトリプシンを中和し、EBを穏やかにピペッティングして、細胞を解離した。その後、細胞を1000 rpmで5分間遠心分離し、10ng/ml VEGFおよび5 ng/ml bFGFを添加したStemPro-34に再懸濁した。その後、細胞をフィブロネクチンでコートした12ウェルプレートに5×105細胞/ウェルで播種し、37℃、5%CO2下で2日間インキュベートした。次いで、Stemfect RNA transfection kitを用いて、製造者(Stemgent)の指示に従って、miRNA応答性オフスイッチmRNAを細胞に導入した。具体的には、25μl / tube Stemfect Transfection Buffer を2つの滅菌した1.5ml tubeへ入れた。次いで、一方のtubeに、2μlのStemfect RNA Transfection Reagentを加えてバッファーと混合した。もう一方のtubeには、0.5 μlもしくは1.0 μl の100 ng/ μl ピューロマイシンmRNA(Puromycin)と0.5 μl~2.0 μlの100 ng/μl miR-1応答性Bim mRNA(miR-1-HsBimEL)を加えて、バッファーと混合した。希釈したTransfection Reagent溶液を希釈したmRNA溶液に加えて混合した。混合物を室温で15分間インキュベートして、mRNA complexを完成させた。その間に、培養培地を500μlのfreshな培地(10ng/ml VEGFおよび5 ng/ml bFGFを添加したStemPro-34(抗生物質不含))に交換しておき、15分経った時点で、mRNA complexをwellに加えて、37℃、5%CO2下で4時間インキュベートした。その後、培地を除き、細胞をIMDMで一度洗浄してから、ピューロマイシンを添加した500μlのfreshな培地(10ng/ml VEGFおよび5 ng/ml bFGFを添加したStemPro-34)をウェルに加えた。2日間培養し、その後、TNTの発現について解析を行った。
マウスの新生仔より単離した心臓をneonatal Heart dissociation Kit (Miltenyi Biotech)を用いて、製造者の指示に従って単一細胞へと分離後、 24ウェルプレートに2×105細胞/ウェルで播種し、37℃でインキュベートした。翌日、 100 ngのmiR-1-, miR-143-3p-, miR-208a-, miR-208b-およびmiR-499a-5p-応答性オフスイッチ(BFP)を100 ng EGFP mRNAと共にStemfect RNA transfection kit (Stemgent)を用いて、製造者の指示に従って導入した。4時間後、細胞を洗浄後、DMEM+10%FBSを添加し、 1日間培養した。得られた細胞を、 0.25%Trypsinで2分間処理し、BFPおよびEGFPの蛍光強度についてFACSによる解析を行った。
その結果、 miR-1-, miR-143-3p-, miR-208a-, miR-208b-およびmiR-499a-5p-応答性オフスイッチを導入した細胞では、EGFPの蛍光強度が高い細胞において、BFPの蛍光強度が低下する細胞が見られた(図10)。従って、 miR-1-BFP, miR-208b-BFP, miR-208a-BFPおよびmiR-499a-5p-BFPは、心筋細胞を含む心臓に含有される細胞を特異的に認識できることが示唆された。
Claims (28)
- miRNA応答性mRNAを細胞群に導入する工程を含む、心筋細胞の選別方法であって、当該miRNA応答性mRNAが下記:
(i) 心筋細胞で特異的に発現しているmiRNAによって特異的に認識される核酸、および
(ii) 遺伝子のコード領域に対応する核酸
を含む配列からなり、
ここで、当該(ii)の遺伝子のコード領域に対応する核酸のタンパク質への翻訳が当該(i)の核酸配列により制御されている、方法。 - 前記miRNA応答性mRNAが、miRNA応答性オフスイッチmRNAである、請求項1に記載の方法。
- 前記(i)および(ii)の核酸が、5'から3'の方向にこの順序で連結されている、請求項1または2に記載の方法。
- 前記(i)の心筋細胞で特異的に発現しているmiRNAが、miR-1, miR-208a, miR-208bおよびmiR-499a-5pからなる群から選択される1またはそれ以上のmiRNAである、請求項1~3のいずれか1項に記載の方法。
- 前記(ii)の遺伝子が、蛍光タンパク質をコードする遺伝子、アポトーシス誘導遺伝子および自殺遺伝子からなる群から選択される1またはそれ以上の遺伝子である、請求項1~4のいずれか1項に記載の方法。
- 前記蛍光タンパク質をコードする遺伝子が、青色蛍光タンパク質(BFP)をコードする遺伝子である、請求項5に記載の方法。
- 前記アポトーシス誘導遺伝子が、Bimタンパク質をコードする遺伝子である、請求項5に記載の方法。
- 薬剤耐性遺伝子のコード領域に対応する核酸を含む配列からなるmRNAを前記細胞群に導入する工程をさらに含む、請求項1~7のいずれか1項に記載の方法。
- 前記薬剤耐性遺伝子が、抗生物質耐性遺伝子である、請求項8に記載の方法。
- 前記抗生物質耐性遺伝子が、ピューロマイシン耐性遺伝子またはブラストサイジン耐性遺伝子である、請求項9に記載の方法。
- 前記工程(a)の細胞群が、多能性幹細胞から分化誘導させた細胞群である、請求項1~10のいずれか1項に記載の方法。
- 心筋細胞の製造方法であって、下記:
(a) miRNA応答性mRNAを細胞群に導入する工程、および
(b) 工程(a)のmRNAから翻訳されたタンパク質の量に基づいて当該細胞を選別する工程を
含み、
ここで、当該miRNA応答性mRNAが下記:
(i) 心筋細胞で特異的に発現しているmiRNAによって特異的に認識される核酸、および
(ii) 遺伝子のコード領域に対応する核酸
を含む配列からなり、
上記工程(a)および(b)を行わない場合と比較して、高純度の心筋細胞が得られる、方法。 - 前記miRNA応答性mRNAが、miRNA応答性オフスイッチmRNAである、請求項12に記載の方法。
- 前記(i)および(ii)の核酸が、5'から3'の方向にこの順序で連結されている、請求項12または13に記載の方法。
- 前記(i)の心筋細胞で特異的に発現しているmiRNAが、miR-1, miR-208a, miR-208bおよびmiR-499a-5pからなる群から選択される1またはそれ以上のmiRNAである、請求項12~14のいずれか1項に記載の方法。
- 前記(ii)の遺伝子が、蛍光タンパク質をコードする遺伝子である、請求項12~15のいずれか1項に記載の方法。
- 前記蛍光タンパク質をコードする遺伝子が、BFPをコードする遺伝子である、請求項16に記載の方法。
- 前記工程(a)の細胞群が、多能性幹細胞から分化誘導させた細胞群である、請求項12~17のいずれか1項に記載の方法。
- 心筋細胞の製造方法であって、下記:
(a) miRNA応答性mRNAおよび薬剤耐性遺伝子のコード領域に対応する核酸を含む配列からなるmRNAを細胞群に導入する工程、および
(b) 工程(a)の薬剤耐性遺伝子に対応する薬剤の存在下で、工程(a)で得られた細胞群を培養する工程を含み、
ここで、当該miRNA応答性mRNAが下記:
(i) 心筋細胞で特異的に発現しているmiRNAによって特異的に認識される核酸、および
(ii) 遺伝子のコード領域に対応する核酸
を含む配列からなり、
上記工程(a)および(b)を行わない場合と比較して、高純度の心筋細胞が得られる、方法。 - 前記miRNA応答性mRNAが、miRNA応答性オフスイッチmRNAである、請求項19に記載の方法。
- 前記(i)および(ii)の核酸が、5'から3'の方向にこの順序で連結されている、請求項19または20に記載の方法。
- 前記(i)の心筋細胞で特異的に発現しているmiRNAが、miR-1, miR-208a, miR-208bおよびmiR-499a-5pからなる群から選択される1またはそれ以上のmiRNAである、請求項19~21のいずれか1項に記載の方法。
- 前記(ii)の遺伝子が、アポトーシス誘導遺伝子および/または自殺遺伝子である、請求項19~22のいずれか1項に記載の方法。
- 前記アポトーシス誘導遺伝子が、Bimタンパク質をコードする遺伝子である、請求項23に記載の方法。
- 前記薬剤耐性遺伝子が、抗生物質耐性遺伝子である、請求項19~24のいずれか1項に記載の方法。
- 前記抗生物質耐性遺伝子が、ピューロマイシン耐性遺伝子またはブラストサイジン耐性遺伝子である、請求項25に記載の方法。
- 前記工程(a)の細胞群が、多能性幹細胞から分化誘導させた細胞群である、請求項19~26のいずれか1項に記載の方法。
- miRNA応答性mRNAを含む、心筋細胞純化用キットであって、当該miRNA応答性mRNAが下記:
(i) 心筋細胞で特異的に発現しているmiRNAによって特異的に認識される核酸、および
(ii) 遺伝子のコード領域に対応する核酸
を含む配列からなる、キット。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15764434.5A EP3121276B1 (en) | 2014-03-20 | 2015-03-20 | Cardiomyocyte sorting method |
JP2016508823A JP6612736B2 (ja) | 2014-03-20 | 2015-03-20 | 心筋細胞の選別方法 |
US15/127,134 US10538740B2 (en) | 2014-03-20 | 2015-03-20 | Method for sorting cardiomyocytes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014058926 | 2014-03-20 | ||
JP2014-058926 | 2014-03-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015141827A1 true WO2015141827A1 (ja) | 2015-09-24 |
Family
ID=54144788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/058466 WO2015141827A1 (ja) | 2014-03-20 | 2015-03-20 | 心筋細胞の選別方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US10538740B2 (ja) |
EP (1) | EP3121276B1 (ja) |
JP (1) | JP6612736B2 (ja) |
WO (1) | WO2015141827A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016114354A1 (ja) * | 2015-01-14 | 2016-07-21 | 国立大学法人京都大学 | 骨格筋前駆細胞の選択方法 |
WO2019013294A1 (ja) * | 2017-07-12 | 2019-01-17 | 国立大学法人京都大学 | 高発現性mRNAスイッチ |
WO2019031595A1 (ja) * | 2017-08-10 | 2019-02-14 | 国立大学法人京都大学 | 神経前駆細胞の選別方法 |
WO2019189545A1 (ja) | 2018-03-30 | 2019-10-03 | 国立大学法人京都大学 | 細胞の製造方法 |
JP2019528736A (ja) * | 2016-09-16 | 2019-10-17 | アイカーン スクール オブ メディスン アット マウント サイナイIcahn School of Medicine at Mt. Sinai | modRNAの細胞特異的発現 |
WO2020032185A1 (ja) | 2018-08-10 | 2020-02-13 | 国立大学法人京都大学 | カチオン性脂質を用いた心筋細胞へのトランスフェクション方法 |
WO2023074873A1 (ja) * | 2021-10-29 | 2023-05-04 | 国立大学法人京都大学 | 細胞純化方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009066758A1 (ja) * | 2007-11-22 | 2009-05-28 | Japan Science And Technology Agency | 低分子rnaによる細胞または人工細胞モデルでの翻訳制御システム |
WO2011154553A2 (en) * | 2010-06-11 | 2011-12-15 | Cellartis Ab | Novel micrornas for the detection and isolaton of human embryonic stem cell-derived cardiac cell types |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020115213A1 (en) * | 1998-08-14 | 2002-08-22 | Northeastern Ohio Universities Of Medicine | Engraftable neural progenitor & stem cells for brain tumor therapy |
AU2006262329B2 (en) | 2005-06-22 | 2011-04-07 | Asterias Biotherapeutics, Inc. | Differentiation of primate pluripotent stem cells to cardiomyocyte-lineage cells |
EP2206724A1 (en) | 2005-12-13 | 2010-07-14 | Kyoto University | Nuclear reprogramming factor |
US20090186414A1 (en) | 2008-01-18 | 2009-07-23 | Deepak Srivastava | Methods of Generating Cardiomyocytes and Cardiac Progenitors and Compositions |
WO2009118928A1 (en) | 2008-03-26 | 2009-10-01 | Kyoto University | Efficient production and use of highly cardiogenic progenitors and cardiomyocytes from embryonic and induced pluripotent stem cells |
JP2010158206A (ja) | 2009-01-08 | 2010-07-22 | National Institute Of Advanced Industrial Science & Technology | ヒト心筋前駆細胞の選別方法 |
EP3460064B8 (en) * | 2011-04-03 | 2024-03-20 | The General Hospital Corporation d/b/a Massachusetts General Hospital | Efficient protein expression in vivo using modified rna (mod-rna) |
US20150184129A1 (en) | 2012-07-17 | 2015-07-02 | Kyoto University | Novel cardiomyocyte marker |
EP3613862A1 (en) | 2014-01-10 | 2020-02-26 | Kyoto University | Method for distinguishing desired cell type using expression of mirna as indicator |
JP6893633B2 (ja) | 2014-07-16 | 2021-06-23 | 国立大学法人京都大学 | 分化細胞の抽出方法 |
US10501811B2 (en) | 2015-04-22 | 2019-12-10 | Kyoto University | Method for sorting tissue cells |
-
2015
- 2015-03-20 EP EP15764434.5A patent/EP3121276B1/en active Active
- 2015-03-20 JP JP2016508823A patent/JP6612736B2/ja active Active
- 2015-03-20 WO PCT/JP2015/058466 patent/WO2015141827A1/ja active Application Filing
- 2015-03-20 US US15/127,134 patent/US10538740B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009066758A1 (ja) * | 2007-11-22 | 2009-05-28 | Japan Science And Technology Agency | 低分子rnaによる細胞または人工細胞モデルでの翻訳制御システム |
WO2011154553A2 (en) * | 2010-06-11 | 2011-12-15 | Cellartis Ab | Novel micrornas for the detection and isolaton of human embryonic stem cell-derived cardiac cell types |
Non-Patent Citations (6)
Title |
---|
BABIARZ J.E. ET AL.: "Determination of the human cardiomyocyte mRNA and miRNA differentiation network by fine-scale profiling.", STEM CELLS DEV., vol. 21, no. 11, 2012, pages 1956 - 1965, XP055225626, ISSN: 1547-3287 * |
ENDO K. ET AL.: "A versatile cis-acting inverter module for synthetic translational switches.", NAT. COMMUN., vol. 4, no. 2393, 2013, pages 1 - 9, XP055225627 * |
HIROAKI KATO ET AL.: "Jinko RNA Switch ni yoru Hon'yaku Seigyo no Kochiku Oyobi Jinko Saibo Model no Soshutsu ni Mukete", JOURNAL OF JAPANESE BIOCHEMICAL SOCIETY, 2007, pages JP- 1322, XP008184661 * |
KENJI MIKI ET AL.: "Efficient detection and purification of cells by synthetic microRNA switches", REGENERATIVE MEDICINE, February 2015 (2015-02-01), pages 188, XP008185727 * |
MIKI K. ET AL.: "Efficient detection and purification of cell populations using synthetic microRNA switches.", CELL STEM CELL, vol. 16, no. 6, June 2015 (2015-06-01), pages 699 - 711, XP055225629, ISSN: 1934-5909 * |
SYNNERGREN J. ET AL.: "Expression of microRNAs and their target mRNAs in human stem cell - derived cardiomyocyte clusters and in heart tissue.", P HYSIOL. GENOMICS, vol. 43, no. 10, 2011, pages 581 - 594, XP055225625, ISSN: 1094-8341 * |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016114354A1 (ja) * | 2015-01-14 | 2016-07-21 | 国立大学法人京都大学 | 骨格筋前駆細胞の選択方法 |
US10620109B2 (en) | 2015-01-14 | 2020-04-14 | Kyoto University | Method for selecting skeletal muscle progenitor cell |
US11299749B2 (en) | 2016-09-16 | 2022-04-12 | Icahn School Of Medicine At Mount Sinai | Cell-specific expression of modRNA |
EP4316587A3 (en) * | 2016-09-16 | 2024-04-24 | Icahn School of Medicine at Mount Sinai | Cell-specific expression of modrna |
JP2019528736A (ja) * | 2016-09-16 | 2019-10-17 | アイカーン スクール オブ メディスン アット マウント サイナイIcahn School of Medicine at Mt. Sinai | modRNAの細胞特異的発現 |
AU2017326535B2 (en) * | 2016-09-16 | 2023-08-24 | Icahn School Of Medicine At Mount Sinai | Cell-specific expression of modrna |
EP3512567A4 (en) * | 2016-09-16 | 2020-03-18 | Icahn School of Medicine at Mount Sinai | SPECIFIC EXPRESSION OF AN ARNMOD CELL |
JP7432362B2 (ja) | 2016-09-16 | 2024-02-16 | アイカーン スクール オブ メディスン アット マウント サイナイ | modRNAの細胞特異的発現 |
JPWO2019013294A1 (ja) * | 2017-07-12 | 2020-10-22 | 国立大学法人京都大学 | 高発現性mRNAスイッチ |
JP7318931B2 (ja) | 2017-07-12 | 2023-08-01 | 国立大学法人京都大学 | 高発現性mRNAスイッチ |
WO2019013294A1 (ja) * | 2017-07-12 | 2019-01-17 | 国立大学法人京都大学 | 高発現性mRNAスイッチ |
JPWO2019031595A1 (ja) * | 2017-08-10 | 2020-07-09 | 国立大学法人京都大学 | 神経前駆細胞の選別方法 |
JP7236738B2 (ja) | 2017-08-10 | 2023-03-10 | 国立大学法人京都大学 | 神経前駆細胞の選別方法 |
WO2019031595A1 (ja) * | 2017-08-10 | 2019-02-14 | 国立大学法人京都大学 | 神経前駆細胞の選別方法 |
WO2019189545A1 (ja) | 2018-03-30 | 2019-10-03 | 国立大学法人京都大学 | 細胞の製造方法 |
JPWO2019189545A1 (ja) * | 2018-03-30 | 2021-03-25 | 国立大学法人京都大学 | 細胞の製造方法 |
JP7440868B2 (ja) | 2018-03-30 | 2024-02-29 | 国立大学法人京都大学 | 細胞の製造方法 |
WO2020032185A1 (ja) | 2018-08-10 | 2020-02-13 | 国立大学法人京都大学 | カチオン性脂質を用いた心筋細胞へのトランスフェクション方法 |
CN112639111B (zh) * | 2018-08-10 | 2023-07-21 | 国立大学法人京都大学 | 使用阳离子性脂质的转染心肌细胞的方法 |
EP3842538A4 (en) * | 2018-08-10 | 2022-06-08 | Kyoto University | METHOD OF TRANSFECTION INTO CARDIOMYOCYTES USING CATIONIC LIPID |
CN112639111A (zh) * | 2018-08-10 | 2021-04-09 | 国立大学法人京都大学 | 使用阳离子性脂质的转染心肌细胞的方法 |
WO2023074873A1 (ja) * | 2021-10-29 | 2023-05-04 | 国立大学法人京都大学 | 細胞純化方法 |
Also Published As
Publication number | Publication date |
---|---|
EP3121276A4 (en) | 2017-09-13 |
JPWO2015141827A1 (ja) | 2017-04-13 |
EP3121276A1 (en) | 2017-01-25 |
US10538740B2 (en) | 2020-01-21 |
US20170369846A1 (en) | 2017-12-28 |
EP3121276B1 (en) | 2019-04-17 |
JP6612736B2 (ja) | 2019-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6612736B2 (ja) | 心筋細胞の選別方法 | |
EP3042951B1 (en) | New method for inducing dopamine-producing neural precursor cells | |
JP2019058192A (ja) | 神経分化誘導用の多能性幹細胞 | |
JP6429280B2 (ja) | 効率的な心筋細胞の誘導方法 | |
EP2938721B1 (en) | Method for inducing astrocytes | |
JP6883791B2 (ja) | 骨格筋前駆細胞の選択方法 | |
JP6373253B2 (ja) | 新規心筋細胞マーカー | |
US20200056248A1 (en) | Method for sorting tissue cells | |
JP6025067B2 (ja) | 新規心筋細胞マーカー | |
JP2013527746A (ja) | 多能性幹細胞から骨格筋または骨格筋前駆細胞への分化誘導法 | |
JP7236738B2 (ja) | 神経前駆細胞の選別方法 | |
JP6730709B2 (ja) | 気道上皮細胞の分化誘導法 | |
JP6780197B2 (ja) | 新規成熟心筋細胞マーカー | |
JPWO2014192925A1 (ja) | 効率的な内皮細胞の誘導方法 | |
WO2022102742A1 (ja) | 骨格筋系譜細胞および骨格筋幹細胞の高効率純化用細胞表面マーカーおよびその利用 | |
WO2020090836A1 (ja) | 細胞の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15764434 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016508823 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015764434 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015764434 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15127134 Country of ref document: US |